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CHAPTER 1 - INTRODUCTION
Preterm birth (PTB) is defined as occurring prior to 37 weeks of gestation (1).
With a rate of 11.39% in the United States (2), PTB is the leading cause of perinatal
mortality (3). The infants that survive PTB have increased risk of developing short-term
and lifelong complications (4-6), which greatly increases the number of years they lose
due to illness, disability or early death (7). Preterm birth is a syndrome of multiple
etiologies (8), which makes studying its pathophysiological mechanisms more
challenging. However, the common factor of inflammation underlies many of these
etiologies, including decidual senescence, infection, stress, allergy, and breakdown of
fetal-maternal tolerance.
Inflammation at the maternal-fetal interface during labor has been well
substantiated by the documented increased bioavailability of cytokines and chemokines
and an influx of immune cells, including macrophages, neutrophils, and T cells, into the
reproductive tissues (9-11). Inflammation has been shown to promote initiation of the
common pathway of parturition (12) (Figure 1) via up-regulation of matrix
metalloproteinases (13-18) and prostaglandins (19, 20).

Sterile intraamniotic

inflammation occurring in the absence of detectable microorganisms is more prevalent
than microbial-associated intraamniotic inflammation in patients with preterm labor and
intact fetal membranes (21).

Innate immune response initiates sterile inflammation

when endogenous danger signals derived from necrosis or cellular stress (22), referred
to as damage-associated molecular pattern molecules (DAMPs) (23) or alarmins (24),
bind to their respective pattern recognition receptors (PRRs) and trigger proinflammatory cascade.
We aimed to determine 1) whether alarmins are capable of inciting sterile
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inflammation of the chorioamniotic membranes leading to pro-labor changes.

In

addition to initiating innate immune response, alarmins can also activate adaptive
immunity (25, 26). We hypothesized that the release of alarmins activates invariant
natural killer (iNKT) cells (27) – unique immune cells that have characteristics of both
innate and adaptive immunity – leading to labor.

Therefore, our next aim was to

determine whether 2) activation of iNKT cells leads to sterile inflammation and
precipitates labor. Secretion of alarmins is one of the hallmarks of senescent cells (2830), which have been implicated in the process of murine parturition (31). Thus, our
final aim was 3) to investigate whether chorioamniotic membranes obtained from
women who underwent preterm labor exhibit cellular senescence.

Figure 1: Inflammation as a common factor of multiple etiologies of preterm birth. We
propose that decidual senescence, among other pro-inflammatory conditions, causes the
release of alarmins at the maternal-fetal interface which induces iNKT cell activation and sterile
inflammation initiating the common pathway of parturition.
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CHAPTER 2 - HMGB1 INDUCES STERILE INFLAMMATION AT THE MATERNALFETAL INTERFACE
Introduction
Innate immune response can initiate sterile inflammation when danger signals
(32) are sensed by pattern recognition receptors (PRRs) (33), which leads to activation
of the inflammasome complex and caspase-1-mediated maturation of IL1β (34-39).
Expression of the inflammasome components is upregulated in the chorioamniotic
membranes of patients who underwent spontaneous term labor when compared to term
delivery without labor (40). Concentration of caspase-1 is elevated in the amniotic fluid
of patients with spontaneous preterm labor and intraamniotic infection/inflammation
when

compared

to

patients

who

delivered

preterm

without

intraamniotic

infection/inflammation or those who delivered at term (41). Finally, elevated amniotic
fluid IL1 β in term spontaneous labor was demonstrated over two decades ago (42-45).
However, the danger signals that initiate the inflammasome-mediated release of IL1β in
the chorioamniotic membranes remain unknown.
High mobility group box 1 (HMGB1) is an evolutionary conserved protein that
stabilizes nucleosome formation and facilitates gene transcription while localized to the
nucleus, but acts as an alarmin when released extracellularly (46). HMGB1 can be
either passively released during cell necrosis or actively exocytosed by immune cells to
initiates pro-inflammatory intracellular signaling in multiple cell types by binding their cell
surface PRRs – RAGE, TLR2, and TLR4 (47, 48).

In macrophages, HMGB1 was

shown to stimulate production of TNF, IL8, IL6, and IL1β (49). In neutrophils, HMGB1
increases levels of TNF, IL8, and IL1β (50), enhances adhesion and migration (51), and
upregulate NF-κB (50). HMGB1 also upregulates NF-κB and induces secretion of TNF,
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IL8, and IL6 in dendritic cells (52), and promotes Th1 differentiation in both dendritic
cells and T cells (52). Finally, HMGB1 was demonstrated to upregulate expression of
VCAM-1, ICAM-1, RAGE and NF-κB and to increase production of TNF and IL8 in
endothelial cells (53).
Transcriptomic profiling has identified HMGB1 as a predicted upstream regulator
of the inflammatory response in the choriodecidua during term labor (54). Sterile intraamniotic inflammation in patients with preterm labor and intact membranes is
associated with elevated levels of HMGB1 in the amniotic fluid (21). Amniotic fluid
HMGB1 concentration is also increased in patients at term with clinical chorioamnionitis
(55) and in patients with preterm prelabor rupture of membranes (PPROM) (56).
Furthermore, extranuclear expression of HMGB1 is upregulated in the preterm cervix
(57), extracellular HMGB1 promotes migration of cord blood CD34+ cells (58), and
tracheal aspirates from premature infants that develop bronchopulmonary dysplasia
contain elevated HMGB1 (59). Therefore, we hypothesized that HMGB1 can induce
sterile inflammation of the chorioamniotic membranes leading to preterm labor and
neonatal complications. In support of this hypothesis, our recent findings demonstrate
that intraamniotic injections of HMGB1 increase the rate of preterm birth and neonatal
mortality in mice (60). Herein, we aimed to explore the molecular mechanisms behind
these adverse effects of HMGB1, specifically whether HMGB1 is capable of inducing
sterile inflammation of the human chorioamniotic membranes via inflammasomemediated release of IL1β.
Materials and Methods
Human subjects
Chorioamniotic membranes were obtained from women who underwent elective
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caesarian sections without labor and were provided with written informed consent.
Samples were collected from the Bank of Biological Specimens of the Perinatology
Research Branch, an intramural program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, National Institutes of Health, U. S.
Department of Health and Human Services (NICHD/NIH/DHHS), Wayne State
University, and The Detroit Medical Center (Detroit, MI, USA). The Institutional Review
Boards of NICHD and Wayne State University (Detroit, MI, USA) approved the
collection and use of biological materials for research purposes. Non-laboring status
was confirmed by the absence of regular uterine contractions at a frequency of at least
two contractions every 10 minutes and the lack of cervical dilatation. Patients with
multiple pregnancies or with deliveries prior to 37 weeks of gestation were excluded.
The detailed patient demographics information is contained in Table 1.
Table 1: The demographical data of patients whose samples were used for the HMGB1
study
25 (19-33)
Age (years)
31.5 (20.4-42-.5)
Body mass index (kg/m2)
38.93 (39.4-37.1)
Gestational age at delivery (weeks)
3225 (2745-3880)
Newborn weight (g)
Race
African-American
91.4% (21/23)
Caucasian
8.6% (2/23)
Hispanic
0% (0/23)
Asian
0% (0/23)
Other
0% (0/23)
17.4% (4/23)
Primiparity
100% (23/23)
C-section
100% (23/23)
Absence of chorioamnionitis
17.4% (4/23)
Smoking During Pregnancy
Age, body mass index, gestational age at delivery, and newborn
weight are shown as mean (min-max). Race, primiparity, Csection, absence of chorioamnionitis, and smoking during
pregnancy are shown as percent (positive/total).

In vitro HMGB1 treatment
Chorioamniotic membrane samples obtained from non-laboring, term deliveries,
were spread out flat onto a sterile cutting board. A dermatological biopsy punch (12mm
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Acu-Punch, Acuderm Inc., Fort Lauderdale, FL, USA) was used to expunge tissue
explants from the chorioamniotic membranes. The explants were treated with 500μL of
1x Dulbecco’s Modified Eagle Medium (DMEM) (Corning, Manassas, VA, USA)
containing 10% Fetal Bovine Serum (FBS) (Gibco, Life Technologies Corporation,
Grand Island, NY, USA) and 1% penicillin/streptomycin (Gibco) either with or without
Ultra-Pure HMGB1 (Catalog # REHM050, IBL International Corporation, Toronto, ON,
Canada). Explants were placed in a falcon 24 well plate (Corning) and incubated for
24-hours in a humidified 5% CO2 incubator.
ELISA
Mature IL1β and IL6 released from the chorioamniotic membrane explants into
the culture media (n=6-13) was quantified using IL1β ELISA kit (R&D Systems, Inc.
Minneapolis, MN, USA) and IL6 ELISA kit (R&D Systems, Inc.). The sensitivities of
detection were <1pg/mL and <0.70pg/mL, respectively. Caspase-1 concentrations in
the chorioamniotic membranes homogenized in their conditioning media (n=9) was
determined using caspase-1 ELISA kit (Cloud Clone, Houston, TX, USA) with sensitivity
of detection of <0.112 ng/ml. All ELISAs were run according to the manufacturers’
protocols. Briefly, recombinant human standards and the samples were incubated in
duplicate wells of the 96-well microplates pre-coated with immobilized monoclonal
antibodies specific for target analytes. After washing the unbound substances, enzymeconjugated anti-IL1β, anti-IL6 or anti-caspase-1 antibodies were added to the wells.
After incubation, assay plates were washed again to remove the unbound antibodies,
followed by the addition of a substrate solution, which produced color in proportion to
the amount of bound target analytes. Finally, sulfuric acid solution was added to arrest
the color development and the microplates were read using a programmable

7
spectrophotometer (SpectraMax M5 Multi-Mode Microplate Reader, Molecular Devices,
Sunnyvale, CA, USA).
RT-PCR
TRIzol® (Life Technologies Corporation), Qiagen RNeasy® Kit (Qiagen,
Valencia, CA, USA), RNase-Free DNase Sets (Qiagen), and QIAshredders (Qiagen)
were used for total RNA extraction from the chorioamniotic membrane (n=5-8) on
QIAcube (Qiagen).

RNA concentration was determined with the NanoDrop® 1000

spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and RNA integrity was
assessed with the Bioanalyzer 2100 (Agilent Technologies, Wilmington, DE, USA).
Table 2: The list of primers used for RT-PCR in the HMGB1 study
Gene
NOD1
NOD2
NLRP1
NLRP3
NLRC4
AIM2
CASP1
CASP4
IL1B
IL18
IL6
INFG
IL1A
TNF
TLR2
TLR4
AGER (RAGE)
NFKB1
PTGS2
MMP9
GAPDH
ACTB
RPLPO
HMGB1
S100A12
HSPA1A (HSP70)
HMGB1

Full Name
Nucleotide-Binding Oligomerization DomainContaining Protein 1
Nucleotide-Binding Oligomerization DomainContaining Protein 2
NLR Family, Pyrin Domain Containing 1
NLR Family, Pyrin Domain containing 3
NLR family, CARD domain containing 4
Absent in Melanoma 2
Caspase 1
Caspase 4
Interleukin 1, Beta
Interleukin 18
Interleukin 6
Interferon, Gamma
Interleukin 1, Alpha
Tumor Necrosis Factor
Toll-Like Receptor 2
Toll-Like Receptor 4
Receptor for Advanced Glycation Endproducts
Nuclear Factor of Kappa Light Polypeptide Gene
Enhancer in B-cells 1
Prostaglandin-Endoperoxide Synthase 2
Matrix Metallopeptidase 9
Glyceraldehyde 3-Phosphate Dehydrogenase
Actin, Beta
Ribosomal Protein, Large, P0
High Mobility Group Box 1
S100 Calcium Binding Protein A12
Heat Shock 70kDa Protein 1A
High Mobility Group Box 1

ID

Lot

hs00196075_m1

730289

hs00223394_m1

1130429

hs00249187_m1
hs00918082_m1
hs00368367_m1
hs00915710_m1
hs00354836_m1
hs01031947_m1
hs00174097_m1
hs99999040_m1
hs00985639_m1
hs00989291_m1
hs99999028_m1
hs00174128_m1
hs00610101_m1
hs00152939_m1
hs00153957_m1

696883
1204490
724373
1014056
1035134
1010522
815049
666991
941055
970586
937514
905231
435401
432491
897932

hs00765730_m1

1208011

hs01573477_m1
hs00234579_m1
hs99999905_m1
hs99999903_01
hs99999902_m1
hs01590761_g1
hs00194525_m1
hs00359163_s1
hs01923466_g1

816998
439744
1335169
984416
1347306
1032400
866042
1310706
946636

The abbreviations and the full names of genes are listed with assay IDs and Lot numbers for each
primer.

The SuperScript® III First-Strand Synthesis System (Life Technologies
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Corporations) and oligo(dT)20 primers (Life Technologies Corporation) was used to
synthesize the cDNA.

Gene expression profiling was performed on the BioMark™

System for high-throughput qRT-PCR (Fluidigm, San Francisco, CA, USA) with
TaqMan® gene expression assays (Applied Biosystems, Life Technologies Corporation)
listed in Table 2.
Immunoblotting
Chorioamniotic membrane explants homogenized in their conditioned medium
(n=9 per group) were heated at 95oC for 5 minutes in NuPAGE® Sample Reducing
Agent (Novex®, Life Technologies Corporation, Carlsbad, CA, USA) and NuPAGE®
LDS Sample Buffer (Novex®, Life Technologies Corporation). NuPAGE® 4-12% BisTris Gel (Catalog # IM-8042, Novex®, Life Technologies Corporation) was used to
perform an SDS-PAGE of the samples and a protein ladder (BioRad Precision Plus
Protein Dual Color Standards, Catalog# 161-0374) in Invitrogen Novex® Mini-Cell (Life
Technologies Corporation) with NuPAGE® MES SDS Running Buffer (Novex®, Life
Technologies Corporation). After electrophoresis, separated proteins were transferred
onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) using NuPAGE® Transfer
Buffer (Novex®, Life Technologies Corporation) diluted in 20% methanol. Transfer was
performed in a Bio-Rad Mini-Protean II Cell (Bio-Rad). Ponceau S solution (SigmaAldrich®, St. Louis, MO, USA) was used to visualize successful protein transfer. The
membranes were blocked with StartingBlockTM T20 (TBS) Blocking Buffer (Thermo
Scientific, Rockford, IL) for 30 minutes and probed with 1:500 mouse anti-CASP-1
monoclonal

antibody

(Catalog

#

MAB6215,

R&D

Systems)

diluted

in

the

StartingBlockTM T20 (TBS) Blocking Buffer overnight at 4°C. After washing with 1X
TBS (Bio-Rad) containing 0.1% Tween-20 (BioRad), the membranes were incubated
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with 1:5000 anti-mouse IgG HRP-linked secondary antibody (Catalog # 7076S, Cell
Signaling, Boston, MA, USA).

Chemiluminescence signals were detected with

ChemiGlow West Reagents (Protein Simple, Santa Clara, CA, USA). Images were
acquired was performed using the FUJIFILM LAS-4000 Imaging System (FUJIFILM
North America Corporation, Valhalla, NY, USA) and semi-quantification was performed
by ImageJ 1.44p (National Institute of Health, USA). Reference gene was probed for 1h
at room temperature with a mouse anti-human GAPDH monoclonal antibody (Catalog #
SC-32233, Santa Cruz Biotechnology, Inc.).
Zymography
Chorioamniotic membrane explants homogenized in their conditioned medium
(n=9 per group) were mixed at 1:1 with a Tris-Glycine SDS Sample Buffer (2x)
(Novex®, Life Technologies Corporation, Carlsbad, CA, USA) and loaded into Novex®
10% Zymogram (Gelatin) Gel (Catalog # EC6175, Novex®, Life Technologies
Corporation) with a protein ladder (BioRad Precision Plus Protein Dual Color Standards,
Catalog# 161-0374). SDS-PAGE was performed in an Invitrogen Novex® Mini-Cell
(Life Technologies Corporation) with Novex® Tris-Glycine SDS Running Buffer
(Novex®, Life Technologies Corporation). After electrophoresis, gels were removed
and incubated for 30 minutes in Novex® Zymograph Renaturing buffer (Novex®, Life
Technologies Corporation), followed by an additional 30-minute incubation in Novex®
Zymograph Developing Buffer (Novex®, Life Technologies Corporation), both with a
gentle agitation.

Gels were then placed in a freshly made developing buffer and

incubated overnight at 37°C. After overnight incubation, gels were washed 3x in ddH2O
with a gentle agitation, for 5 minutes each. Deionized water was removed and gels
were stained for four hours with SimplyBlue™ SafeStain (Invitrogen, Life Technologies
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Corporation). Once staining was complete, gels were washed 2x for 1 hour in ddH2O.
Images were taken using Alpha Innotech FluorChem™ SP (ProteinSimple, San Jose,
CA, USA) and semi-quantified by ImageJ 1.44p (National Institute of Health, USA).
Trichromic staining
Chorioamniotic membrane explants embedded into paraffin blocks were cut into
five-μm-thick sections, placed onto salinized slides, deparaffinized with xylene, and
hydrated with ethanol and water.

The staining was performed on the Dako

AutostainerPlus (Dako, Carpinteria, CA, USA) using Masson’s Trichrome Stain Kit
(American MasterTech, Lodi, CA, USA) as per the manufacturer’s protocol. Briefly,
sections were incubated overnight in Bouin solution at room temperature, rinsed, and
stained with Weigert’s hematoxylin for 5 minutes. The slides were then rinsed again in
water and stained with Biebrich Scarlet-Acid Fuchsin Solution for 15 minutes, rinsed a
third time, and incubated with phosphomolybdic/phosphotungstic acid for 15 min. Final
staining with Aniline Blue Stain for 10 minutes was followed by another rinse and
incubation in 1% acetic acid for 5 minutes. The sections were then dehydrated in a
series of alcohol baths, cleared with Xylene, and cover slipped. The images were taken
using the Pannoramic MIDI Digital Slide Scanner (PerkinElmer, Inc., Waltham, MA,
USA) at 40X magnification.
Statistical analyses
Statistical analyses were performed using SPSS, Version 21.0 (IBM Corporation,
Armonk, NY, USA), GraphPad Prism 6 Software (GraphPad Software, Inc., La Jolla,
CA, USA), and R open-source software environment. For gene expression data, Ct
values over technical replicates were averaged and gene expressions relative to
reference (BACT, GAPDH, RPLPO) were quantified by subtracting target gene Ct
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values from mean reference gene Ct values within the same sample. A Shapiro–Wilk
test was performed to determine whether data were normally distributed and all
normally distributed data were analyzed by the paired Student’s t-test. Data that did not
follow normal distribution were analyzed either by Wilcoxon signed-rank test for
matched samples or by Mann-Whitney U test for unmatched samples.

A value of

p<0.05 was considered statistically significant.
Results
In vitro incubation with HMGB1 causes secretion of mature IL1β and IL6 by the
chorioamniotic membranes
We first determined the concentration of HMGB1 that caused the release of proinflammatory cytokines by the chorioamniotic membranes in vitro.
It has been demonstrated that 10 and 50ng/mL HMGB1 can induce the release
of pro-inflammatory cytokines such as IL6 and IL8 from the chorioamniotic membranes
(61).
lowest

A previous study showed that amniotic fluid concentrations of HMGB1 were
in

women

with

PTL

with

intact

membranes

and

no

intra-amniotic

infection/inflammation (median 0.98ng/mL) and highest in women with PTL with
PPROM and intra-amniotic infection/inflammation (median 7.3ng/mL) (56). We used
membrane explants from women who delivered at term without labor to test HMGB1
concentrations ranging from 0-1000 ng/mL and then measure released mature IL1β
(Figure 2A) and IL6 (Figure 2B). We found that concentrations in the ng/mL range were
not effectively inducing cytokine secretion from the chorioamniotic membrane tissue
explants. However, a higher concentration of 25μg/mL significantly increased secretion
of mature IL1β (Figure 2C) and IL6 (Figure 2D) from the chorioamniotic membrane
explants in vitro. We found that 50μg/mL of HMGB1 increased IL1β secretion even
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further (Figure 2C) and chose to use this concentration for the subsequent experiments.
Therefore, these data show that incubation with a concentration of 50μg/mL of HMGB1
is capable of inducing sterile inflammation of the chorioamniotic membranes observed
as secretion of mature IL1β and IL6 from the chorioamniotic membrane explants.

Figure 2: HMGB1 induces release of IL-1β and IL-6 from the chorioamniotic membranes.
The chorioamniotic membranes treated with low doses (0-1000ng/mL) of HMGB1 (A and B) did
not release pro-inflammatory cytokines. Higher concentrations (25μg/mL and 50μg/mL) of
HMGB1 (C and D) significantly enhanced release of mature IL-1β and IL-6.

HMGB1 induces expression of pro-inflammatory cytokines in the chorioamniotic
membranes
We used RT-PCR to confirm that secretion of IL1β and IL6 from the
chorioamniotic membrane explants in response to HMGB1 treatment is also
accompanied by the increased gene expression of IL1B and IL6. To further assess the
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extent of sterile inflammation induced by HMGB1, we explored whether HMGB1
treatment was upregulating expression of other known pro-inflammatory cytokines TNF,
IL1A, IL18, and IFNG.

We also evaluated the expression of NFKB1, a master

transcription factor of inflammation known to promote labor (62-65).
We found that all of these genes were significantly upregulated in response to
HMGB1 (Figure 3) with an exception of IL18. IL18 expression also tended to increase;
however, this tendency did not reach significance (data not shown). Therefore, we
concluded that the sterile inflammation induced by HMGB1 involves upregulation of
multiple pro-inflammatory genes in the chorioamniotic membranes.

Figure 3: HMGB1 up-regulates expression of multiple pro-inflammatory cytokines in the
chorioamniotic membranes. Expression of the pro-inflammatory transcription factor NFKB1
and its downstream targets IL1B, IL6, TNF, IL1A, and IFNG was assessed in the chorioamniotic
membranes treated with HMGB1 (50μg/mL).
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HMGB1 upregulates the expression of inflammasome components and NOD
proteins in the chorioamniotic membranes
Mature IL1β is a resulting product of inflammasome activation (38). Therefore,
we next aimed to investigate whether HMGB1 stimulates release of mature IL1β by
activating the inflammasome pathway. We recently demonstrated that expression of
the inflammasome component NLRP3 (NOD-like receptor family, pyrin domain
containing protein 3) is increased in the chorioamniotic membranes during spontaneous
term labor compared with term delivery without labor (40). In the same study, we also
found that expression of NOD1 (nucleotide-binding oligomerization domain-containing
proteins 1), a NOD protein that directly activates nuclear factor kappa B (NF-κB) to
induce expression of pro-IL1β (66-69), is elevated in term labor.

Therefore, we

hypothesized that HMGB1 may upregulate NLRP3, NOD1, and/or other inflammasome
components and NOD proteins.
We used RT-PCR to measure the expression of NOD1, NOD2, NLRP1, NLRP3,
AIM2, and NLRC4 in the chorioamniotic membrane explants treated with HMGB1. We
found that inflammasome components NLRP1, NLRP3, and AIM2 were significantly
upregulated, while NLRC4 had a tendency to increase, after treatment with HMGB1
(Figure 4). We also found that that both NOD proteins – NOD1 and NOD2 – were
upregulated by HMGB1 (Figure 4). Therefore, we concluded that HMGB1 is capable of
upregulating the expression of specific inflammasome components and NOD proteins in
the chorioamniotic membranes.
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Figure 4: HMGB1 induces expression of the inflammasome components and NOD proteins
in the chorioamniotic membranes. Expression of the inflammasome components NLRP1,
NLRP3, and AIM2, as well as NOD proteins NOD1 was assessed in the chorioamniotic
membranes treated with HMGB1 (50μg/mL).

HMGB1 increases concentration and promotes activation of caspase-1
Inflammasomes activate inflammatory caspases, most notably caspase-1 (38,
70-72).

Caspase-1 is an important enzyme for the IL1 cytokine family, as it is

responsible for cleaving pro-IL1β, pro-IL18, and pro-IL33 into their mature active forms
(73-76).
First, we examined the expression of CASP1 in the chorioamniotic membrane
explants to see whether HMGB1 upregulates caspase-1 at the mRNA level. We found
that CASP1 expression tended to increase following HMGB1 treatment, yet this
tendency did not reach statistical significance (Figure 5A).

We then evaluated the

protein concentration of caspase-1 and found that HMGB1 treatment caused a
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significant increase in total caspase-1 concentration in the chorioamniotic membranes
(Figure 5B). Pro-caspase-1 must be cleaved into two non-identical subunits, p10 and
p20, to become an active enzyme (75, 77). Therefore, we semi-quantified pro- and
active forms of caspase-1 using Western blot. We found that both the immature procaspase-1 and the active caspase-1-p20 were significantly increased after treatment
with HMGB1 (Figure 5C). We concluded that HMGB1 increases concentration and
promotes activation of caspase-1.
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Figure 5: HMGB1 increases concentration and promotes activation of caspase-1 in the
chorioamniotic membranes. Expression of CASP1 gene (A), concentration of total Caspase1 protein (B), and accumulation of active forms of Caspase-1 (p-20 and p-10) (C) were assayed
in the chorioamniotic membranes treated with HMGB1 (50μg/mL).
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HMGB1 upregulates the expression of its own receptors in chorioamniotic
membranes
HMGB1 has been previously shown to interact with RAGE as well as TLR2 and
TLR4 (47, 48). HMGB1 may act through positive feedback, increasing the expression
of its own receptors during inflammation (78). We wanted to examine the expression of
these receptors in the chorioamniotic membranes to see whether receptor expression
correlated with HMGB1 treatment. We found that RAGE and TLR2 were significantly
upregulated in explants after culturing with HMGB1; additionally, TLR4 showed a
tendency to increase as well (Figure 6). We concluded that HMGB1 is capable of
upregulating the expression of its own receptors in vitro.

Figure 6: HMGB1 upregulates the expression of its own receptors in the chorioamniotic
membranes. Expression of particle recognition receptors known to bind HMGB1 – RAGE,
TLR2, and TLR4 was assayed in the chorioamniotic membranes treated with HMGB1
(50μg/mL).

HMGB1 upregulates activity of MMP9 in the chorioamniotic membranes
Matrix metalloproteinase 9 (MMP9) is an enzyme that functions primarily to break
down the extracellular matrix (ECM) and is implicated in the process of labor (13, 7981). Active MMP9 has previously been shown to be increased in spontaneous rupture
of membranes, term and preterm parturition, and microbial invasion (13, 82, 83), as well
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as PPROM (84). MMP9 expression can be stimulated by IL1β in the myometrium and
chorioamniotic membranes (85, 86). We aimed to determine whether HMGB1 could
upregulate the expression and activity of MMP9 in vitro. We found that MMP9 gene
expression is significantly increased in the membrane explants cultured with HMGB1
(Figure 7A). In addition to increased expression, the enzymatic activity of MMP9 was
significantly elevated following HMGB1 treatment (Figure 7B).
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Figure 7: HMGB1 upregulates expression and activity of MMP9 in the chorioamniotic
membranes. Expression (A), and activity of MMP9 (B) was assayed in the chorioamniotic
membranes treated with HMGB1 (50μg/mL) by RT-PCR and zymography, respectively. The
collagen reorganization was examined by the trichrome stain (C).
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This was further demonstrated by the trichrome staining which showed
decreased collagen content (blue) in the chorioamniotic membranes treated with
HMGB1 (Figure 7C). Therefore, we showed that HMGB1 upregulates the expression
and activity of MMP9 in the chorioamniotic membranes.
Discussion
HMGB1 induces sterile inflammation of the chorioamniotic membranes
The study herein affirms that HMGB1 is capable of inducing sterile inflammation
of the chorioamniotic membranes by increasing concentration and/or expression of
multiple pro-inflammatory cytokines including IL1β, IL6, TNF, IL1α, and IFNγ (Figures 2
& 3) and pro-inflammatory PRRs Nod1 and Nod2 (Figure 4).

This inflammatory

cascade may be amplified by positive-feedback via up-regulation of HMGB1 receptors
(RAGE and TLR2) by HMGB1 itself (Figure 6).
Pathogen Associated Molecular Patterns (PAMPs) present during microbial
infection have been shown to act, in part, by promoting release of DAMPs from the
infected cells, including HMGB1 (87, 88).

Interestingly, the evidence suggests that

HMGB1 also participates in mediating infection-induced inflammation at the maternalfetal interface. For instance, chorioamniotic membranes stimulated with LPS have been
shown to release HMGB1 in vitro (61) and intraamniotic administration of LPS
significantly increases HMGB1 concentration in the chorioamniotic membranes in the
sheep model of preterm birth (89).

Additionally, co-expression of HMGB1 and its

receptor RAGE was observed in sites of brain and liver tissue injury of mouse embryos
in murine model of LPS-induce preterm birth (90).

Therefore, HMGB1-induced

signaling is a possible treatment target for both infection- and non-infection-associated
preterm birth.
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The induction of sterile inflammation by HMGB1 occurs via the inflammasome
pathway
We found that the mechanism by which HMGB1 increases release of IL1β from
the chorioamniotic membranes includes up-regulation of inflammasome components.
Inflammasome activation requires two steps: 1) priming via NF-κB-dependent
transcriptional up-regulation of multiple pro-inflammatory targets including pro-IL1β and
inflammasome components; and 2) assembly of the inflammasome components
including pro-capsapse-1, ASC adaptor protein, and specific PRRs, into a functional
complex capable of inducing auto-catalytic cleavage of pro-caspase-1 into its
mature/activated form (91-94). Activated caspase-1 then cleaves pro-IL1β, pro-IL18,
and newly described pro-IL33, into their secreted forms (75-77, 95-105). The data
presented herein suggests that HMGB1 promotes both steps of the inflammasome
activation. The priming by HMGB1 is clearly demonstrated by the increased mRNA
levels of IL1B, NLRP1, NLRP3, and AIM2 (Figures 3 & 4). Although assembly of the
inflammasome complex was not assessed by direct methods such as coimmunoprecipitation,

Fluorescence

Resonance

Energy

Transfer

(FRET),

or

oligomerization assays, the increased production of active form of caspase-1-p20
(Figure 5) and elevated levels of released IL-1β (Figure 2) strongly suggest
inflammasome assembly.

Further studies are needed to establish the direct link

between HMGB1 and assembly of the inflammasome complex.
HMGB1-induced sterile inflammation promotes remodeling of the chorioamniotic
membranes
The data herein demonstrates that HMGB1 promotes inflammasome activation
and IL-1β production at the maternal-fetal interface.

Inflammasome activation is

associated with enhanced production of labor-promoting eicosanoids (106) and
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activation of MMP9 (107). Inflammasome-derived IL-1β induces labor by up-regulating
the expression of cyclooxygenase-2/ prostaglandin synthase 2 (COX2/ PTGS2) (65)
and promoting synthesis of prostaglandin E2 (108-110), as well as by activating the
matrix remodeling enzymes such as MMP9 (111). Therefore, it is not surprising that
systemic administration of IL-1β precipitates preterm birth in mice (45, 112) and
monkeys (113-120). Recently we demonstrated that intraamniotic injections of HMGB1
also induce preterm birth (121). Our current results demonstrate that in vitro stimulation
with HMGB1 causes up-regulation of MMP9 expression, increased MMP9 activity, and
collagen remodeling of the chorioamniotic membranes (Figure 7), which may contribute
to membrane rupture. However, we did not observe significant up-regulation of COX2
with HMGB1 treatment (data not shown). Further studies are required to determine the
exact mechanism by which HMGB1-induced sterile inflammation promotes labor.
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CHAPTER 3 - S100A12 INDUCES STERILE INFLAMMATION OF THE
CHORIOAMNIOTIC MEMBRANES
Introduction
S100 proteins are calcium triggers or sensory proteins that, upon calcium
dependent activation, regulate the function and/or subcellular distribution of certain
target proteins and peptides (122-124). S100 proteins are sensed as alarmins when
they are released extracellularly (125), exerting pro-inflammatory effects on various cell
types in the paracrine and autocrine manner (126). S100A12, along with S100A8 and
S100A9, belong to a S100 protein subfamily termed calgranulins or myeloid-related
proteins, whose members are linked to innate immune functions by their predominant
expression in cells of myeloid origin (127, 128). S100A12 is known to be expressed in
granulocytes (129), monocytes (130), and select epithelial cells (131).

Although

S100A12 is capable of binding multiple PRRs (132), the receptor for advanced glycation
endproducts (RAGE) is the best studied specific PRR targeted by S100A12 (132, 133).
RAGE is expressed at relatively low levels in homeostasis, but in situations
characterized by enhanced cellular activation or stress, the expression of RAGE
receptor is upregulated (123, 134).

Human S100A12 is markedly amplified in

inflammatory compartments i.e. synovial fluid of inflamed joints (135), and elevated
serum levels of S100A12 are found in patients suffering from various inflammatory,
neurodegenerative, metabolic, and neoplastic disorder (136-141).
In pregnancy, amniotic fluid concentration of S100A12 is elevated in women with
intra-amniotic infection and correlates with the degree of inflammation and severity of
histologic chorioamnionitis (140). S100A12 is also elevated in maternal serum, amniotic
fluid, and infant fecal matter in preeclampsia (142), neonatal sepsis (143), and intestinal
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distress in very-low-birth-weight infants (144), respectively. Furthermore, detection of
elevated S100A12 in the amniotic fluid among four biomarkers termed as “MR score”
was proposed to be a quick and accurate predictor of preterm birth (145). Based on
these association studies, we aimed to determine whether S100A12 is indeed capable
of inducing sterile inflammation of the human chorioamniotic membranes and causes
preterm birth in mice. IL-1β was chosen as a marker of sterile inflammation because its
systemic administration induces PTB (146).

Biologically active form of IL-1β is

produced by cleavage of pro-IL-1β by caspase-1, a protease that itself requires
proteolytic processing by inflammasomes for activation.

We have previously

demonstrated that the increased release of mature IL-1β from the chorioamniotic
membranes obtained from the women who underwent term labor (as opposed to the
women who delivered at term without labor) is associated with increased concentration
of both active caspase-1 and NLRP3 inflammasome in the membrane tissue extracts
(40).
We therefore hypothesized that S100A12 induces sterile inflammation of the
chorioamniotic membranes by up-regulating inflammasome components, which leads to
activation of caspase-1 and subsequent maturation of IL-1β. The aims of this study
were: 1) to determine whether S100A12 induces release of mature IL-1β from the
chorioamniotic membranes; 2) to assess whether S10012A12 increases expression of
the inflammasome components; 3) to evaluate the levels of total and mature casapase1 following S100A12 treatment; 4) to discern the expression of pro-inflammatory and
pro-labor genes in the chorioamniotic membranes treated with S100A12; and 5) to
characterize the effects of S100A12 on gestation length and neonatal complications.
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Materials and Methods
Study population
The chorioamniotic membranes were obtained from women who underwent term
delivery without labor as described in Chapter 2. The demographical characteristics of
the patients are summarized in Table 3.
In vitro S100A12 treatment
The chorioamniotic membrane explants (n=21) were cultured as described in
Chapter 2.

For S100A12 treatment, the media was supplemented with 5μg/mL of

S100A12 (Catalog no. 11143-HNAE-50, Lot no. LCL06NO0926, Life Technologies
Corporation). This concentration was chosen based on previous in vitro experiments
(147-150).
ELISA/ RT-PCR/ Immunoblotting/ Trichromic staining
ELISA, RT-PCR, and immunoblotting experiments were performed as described
in Chapter 2.
Animals and husbandry
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME,
USA) and acclimated for at least two weeks. Breeding took place in the animal facilities
at Wayne State University under specific pathogen-free conditions on a 12-h light, 12-h
dark circadian cycle. Pregnant dams were obtained by placing one or two females (812 weeks old) with a proven fertile male and checked daily between 0800 and 0900
hours for a vaginal plug which resulted from mating during the periovulatory period
(2200-0200 hours). The morning of detection of a vaginal plug was considered the 0
day of gestation and 0.5 days post coitum (dpc). Plugged females were removed from
the mating cage and housed individually with food and water ad libitum. Protocol for
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animal handling and care was approved by the Institutional Animal Care and Use
Committee (IACUC) of Wayne State University (Detroit, MI, USA).
Table 3: Demographic characteristics of the patients whose samples were used for the
S100A12 study.
Race:
African-American
19 (90.5%)
Caucasian
2 (9.5%)
29 (20-40)
Maternal age (years)
189 (102-304)
Maternal weight (kg)
32.7 (20.4-50.6)
Maternal body mass index (kg/m2)
38.9 (37-41.9)
Gestational age at delivery (weeks)
3190 (1775-3820)
Newborn weight (grams)
21 (100%)
C-section
3 (14%)
Acute chorioamnionitis
Age, body mass index, gestational age at delivery, and
newborn weight are shown as mean (min-max). Race,
Primiparity, C-section, and absence of chorioamnionitis are
shown as percent (positive/total).

In vivo S100A12 injections
C57BL/6 plugged females were monitored by weight to confirm pregnancy.
Pregnant dams were injected intraperitoneally at 16.5 dpc with 5µg/mL S100A12 (n=8)
dissolved in a vehicle of 1X sterile PBS. Additional pregnant dams (n=8) were injected
with just the vehicle as a negative control. Following injections, pregnant mice were
recorded by video camera until delivery. Gestational length, duration of active labor,
and the rate of stillbirth were determined based on the video recordings. Gestational
length was defined as the time between detection of the vaginal plug and the
appearance of the first pup in the cage. The duration of active labor was defined as the
time between the appearance of the first pup and the appearance of the last pup of the
litter. The rate of stillbirth was defined as the proportion of pups that were born dead
out of the total number of pups. The surviving pups were weighed at weeks 1, 2, and 3
postpartum and their survival rate was recorded.
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Statistical analyses
Statistical analyses were performed using SPSS, Version 21.0 (IBM Corporation,
Armonk, NY, USA), GraphPad Prism 6 Software (GraphPad Software, Inc., La Jolla,
CA, USA), and R open-source software environment.

A Shapiro–Wilk test was

performed to determine whether the data was normally distributed.

The normally

distributed data were analyzed by the paired Student’s t-test, while those data that did
not follow normal distribution were analyzed by Wilcoxon signed-rank test. Neonatal
mortality was analyzed by Logistic Regression.

A value of p<0.05 was considered

statistically significant.
Results
S100A12 induces release of mature IL-1β from the chorioamniotic membranes in
vitro
We first aimed to determine whether S100A12 is capable of inducing sterile
inflammation of the chorioamniotic membranes. Indeed, release of mature active form
of IL-1β, a marker of sterile inflammation, was drastically elevated (p<0.0001) in those
membranes that were treated with S100A12 in vitro (Figure 8).
Additionally, a four-fold increase (p=0.0009) was observed in the expression of
IL1B gene in the chorioamniotic membranes after S100A12 treatment (Figure 8). This
suggested that S100A12 regulates IL-1β on two levels – maturation of pro-IL-1β
precursor protein and enhancement of IL1B gene transcription.
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Figure 8: S100A12 induces IL-1β secretion from the chorioamniotic membranes. The
chorioamniotic membrane explants were treated with S100A12 (5μg/mL), after which ELISA and
RT-PCR assays were performed to determine the secretion of mature IL-1β and the expression
of IL1B, respectively.

S100A12 increases expression of inflammasome components
Proteolytic processing pro-IL-1β precursor protein into active IL-1β is performed
by a cysteine-aspartic acid protease caspase-1 that must be activated by
inflammasomes.
We assessed expression of the inflammasome components NLRP1, NLRP3,
AIM2, and NLRC4 in the chorioamniotic membranes treated with S100A12 to determine
whether S100A12 stimulates maturation of IL-1β by up-regulation of inflammasomes.
Chorioamniotic membrane explants cultured with S100A12 exhibited significant
increase in NLRP3 expression (p=0.046) and tended to up-regulate NLRP1 (p=0.06)
(Figure 9).

Thus, S100A12 activates transcription of the specific inflammasome

components in the chorioamniotic membranes.
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S100A12 activates caspase-1
In order to evaluate the effect of S100A12 on caspase-1, we first quantified the
concentration of total caspase-1 in the chorioamniotic membrane explants cultured with
S100A12.

Although caspase-1 concentration tended to increase with S100A12

treatment, this tendency was not statistically significant (Figure 10A).

Similarly,

expression of CASP1 gene was not significantly affected by S100A12 treatment (Figure
10B). Western blot analysis was performed to differentiate between pro- (p50) and
mature (p20 and p10) forms of caspase-1. Caspase-1-p20 was significantly elevated in
the chorioamniotic membranes treated with S100A12 (p=0.0154) (Figure 10C). These
results demonstrate that S100A12 promotes activation of caspase-1 in the
chorioamniotic membranes.
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Figure 10: S100A12 activates caspase-1 in the chorioamniotic membranes. Caspase-1
expression in the chorioamniotic membranes treated with S100A12 (5μg/mL) was determined on
the mRNA level by RT-PCR (A) and on the protein level by ELISA (B) and Western blot (C).

Augmented secretion of IL-1β from the chorioamniotic membrane explants
cultured with S100A12 occurs concurrently with increased expression of the
inflammasome subunits and accelerated maturation of caspase-1. Therefore, S100A12
up-regulates expression of inflammasomes, which may cause the demonstrated
activation of caspase-1 and the subsequent release of mature IL-1β.
S100A12 induces NF-κB signaling in the chorioamniotic membranes
Although maturation of IL-1β in the chorioamniotic membranes treated with
S100A12 may occur via the inflammasome-dependent activation of caspase-1,
increased expression of IL1B gene (Figure 8) suggests additional effect of S100A12 on
transcription.
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NF-κB is a transcription fact known to regulate transcription of IL1B (151) as well
as a multitude of other pro-inflammatory mediators, including cytokines, chemokines,
immunoreceptors, proteins involved in antigen presentation, and so on (152). NOD1
and NOD2 are intracellular PRRs that induce nuclear translocation of NF-κB for
initiation of transcription (153). We found that S100A12 increases expression of both
NOD1 (p=0.009) and NOD2 (p=0.0009) in the chorioamniotic membranes. Expression
of NFKB1 gene itself was significantly up-regulated by S100A12 (p=0.001), as was the
expression of two prototypical NFκB targets TNF (p=0.014) and IL6 (p=0.0009).
Expression of several other pro-inflammatory genes that were tested tended to increase
with S100A12 treatment as well, although this tendency did not reach significance
(Figure 11). All together, these data indicate that S100A12 is capable of inducing NFκB-dependent transcriptional activation in the chorioamniotic membranes.

Figure 11: S100A12 induces NF-κB signaling in the chorioamniotic membranes. The
chorioamniotic membranes treated with S100A12 (5μg/ml) were subjected to RT-PCR assay to
determine the expression of NOD proteins (NOD1 and NOD2) as well as of the proinflammatory
transcription
factor NFKB1
and
its targets TNF, IL6, and IL1A, IL18, and IFNG.
S100A12
increases
expression
of its
receptor

31
Propagation of inflammation often requires positive feedback loop, as seen most
strikingly in cytokine storm.

We assessed whether S100A12 treatment enhances

sensitivity of the chorioamniotic membrane to S100A12 itself.

Indeed, S100A12

increased expression of its own receptor, RAGE (p=0.005) (Figure 12). Interestingly,
expression of another putative S100A12 receptor TLR4 (132) was not effected by S100
treatment, while expression of TLR2 (p=0.026) was (Figure 12).

Considering that

transcription of both RAGE (154) and TLR2 (155) is stimulated by NF-κB, it is possible
that S100A12-induced NF-κB signaling leads to up-regulation of these PRRs, which, in
turn, increases cellular sensitivity to various DAMPs, including S100A12 itself.
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Figure 12: S100A12 increases expression of its own receptors in the chorioamniotic
membranes. Expression of the PRRs known to interact with S100A12 (RAGE, TLR2, and
TLR4) was determined by RT-PCR using the chorioamniotic membrane explants treated with
S100A12 (5μg/ml).

S100A12 initiates pro-labor signaling in the chorioamniotic membranes
Labor is characterized by the influx of immune cells and the release of proinflammatory mediators at the maternal-fetal interface.

Since treatment of the

chorioamniotic membranes with S100A12 induces sterile inflammation of the
chorioamniotic membranes, we evaluated whether this inflammation leads to upregulation of pro-labor markers.

Treatment with S100A12 caused up-regulation of
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prostaglandin-endoperoxide synthase 2 (PTGS2), a key enzyme in the biosynthesis of
labor-inducing prostaglandins (Figure 13A).

S100A12 also increased expression of

matrix metallopeptidase 9 (MMP9), the extracellular matrix degradation enzyme that
mediates rupture of the chorioamniotic membranes among other remodeling processes
of labor (Figure 13A). When stained with Masson trichrome stain, the collagen fibers in
the chorioamniotic membrane explants treated with S100A12 appeared less organized
and more degraded (Figure 13B), which is also indicative of pro-labor state.
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Figure 13: S100A12 increases expression of MMP9 and PTGS2 in the chorioamniotic
membranes. The chorioamniotic membranes treated with S100A12 (5μg/mL) were subjected to
RT-PCR assay to determine expression of MMP9 and PTGS2 (A) as well as to Trichromic
Staining to visualize MMP-dependent collagen rearrangement (B).
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S100A12 causes neonatal complications in vivo
Based on the pro-labor effects of S100A12 on the chorioamniotic membrane
explant in vitro, we designed a murine model to determine whether S100A12 is capable
of inducing labor in vivo. In this model, pregnant dams were intraperitoneally injected
either with S100A12 or with PBS as a negative control at late gestation (16.5 dpc). The
S100A12 injections did not precipitate preterm delivery (data not shown). However, the
cohort of mice injected with S100A12 exhibited significantly increased neonatal mortality
(p<0.001) (Figure 14). The pups that survived weighed significantly less three weeks
after birth than the pups from mothers injected with PBS (p<0.001).

Therefore,

intraperitoneal injections of S100A12 at 16.5 dpc do not induce preterm birth in mice,
but cause serious neonatal complications.
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Figure 14: S100A12 confers adverse neonatal effects in vivo. Neonatal mortality was
observed following labor and pup weight were recorded at week 3 post-delivery in the mice that
were intraperitoneally injected with S100A12 (5µg/ml).

Discussion
Major findings
The major findings of this study are: 1) S100A12 is capable of inducing sterile
inflammation of the chorioamniotic membranes confirmed by increased secretion and/or
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expression of pro-inflammatory cytokines IL-1β, IL-1α, TNF, and IL-6, pro-inflammatory
transcription factor NF-κB, and pro-inflammatory NOD proteins NOD1 and NOD2; 2)
S100A12 significantly up-regulates expression of the inflammasome component NLRP3
and tends to up-regulate NLRP1; 3). The up-regulation of inflammasome components
occurs together with elevated expression of pro- and active (p20) forms of
inflammasome-dependent caspase-1; 4) S100A12 up-regulates expression of its own
PRRs RAGE and TLR2, suggesting positive feedback regulation; 5) Chorioamniotic
membranes treated with S100A12 exhibit increased expression of MMP9 and PTGS2
and decreased collagen integrity; 6) The neonates born to mothers who were
intraperitoneally injected with S100A12 in late gestation exhibit higher rate of mortality
and reduced weights three week after delivery.
S100A12 induces inflammasome-associated
chorioamniotic membranes

sterile

inflammation

of

the

Our findings confirm that S100A12 is capable if inducing sterile inflammation of
the chorioamniotic membranes via up-regulation of pro-inflammatory transcription factor
NF-κB and its down-stream targets including IL-1β, IL-1α, TNF, and IL-6, as well as
NOD proteins NOD1 and NOD2 (Figure 11). Interestingly, S100A12-induced sterile
inflammation seems to involve up-regulation of the NLRP3 inflammasome (Figure 9)
and corresponding maturation of caspase-1 (Figure 10). This is in concert with our
previous findings that demonstrate up-regulation of NLRP3 in term spontaneous labor
when compared to term delivery without labor (40) and in preterm labor with
chorioamnionitis when compared to preterm labor without chorioamnionitis (unpublished
data). NLRP3 is a NOD-like receptor capable of responding to a multitude of chemically
and structurally divergent stimuli including, but not limited to, nucleic acids such as fetal
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DNA, crystals such as uric acid, extracellular adenosine triphosphate (ATP), calcium
levels, and ultraviolet radiation (156). Thus, it is not surprising that both HMGB1 and
S100A12 (Figure 4 & 9, respectively) are capable of up-regulating NLRP3.
S100A12 promotes remodeling of the chorioamniotic membranes in vitro and
neonatal complications in vivo
Activation of the NF-κB pathway is known to occur in labor and is central to many
of pro-labor processes (63), including prostaglandin synthesis. The promoter of human
PTGS2 contains two NF-κB response elements (157), which have been demonstrated
to be bound by NF-κB in the myometrial cells stimulated by IL-1β (158). Our results
herein show that S100A12 actives NF-κB signaling (Figure 11) and up-regulates
expression of PTGS2 in the chorioamniotic membranes (Figure 13). Additionally, we
found that S100A12 also up-regulates expression of MMP9 and promotes collagen
rearrangement (Figure 13).

Collagen remodeling contributes to the rupture of

chorioamniotic membranes, which is one of the components of final pathway of labor
(Figure 1). Thus, S200A12 may establish pro-labor environment at the maternal-fetal
interface by promoting both the synthesis of prostaglandins and the membrane
remodeling. However, intraperitoneal injections of S100A12 did not precipitate preterm
birth in mice (data not shown). It was recently found that inducing sterile intraamniotic
inflammation by intraamniotic injections of HMGB1 resulted in increased rate of murine
preterm birth, while intraperitoneal injections of much higher doses of this alarmin did
not affect the rate of preterm delivery (121). Therefore, it is possible that S100A12
needs to be injected intraamniotically in order to induce preterm labor in mice.
Nevertheless, our data herein shows that intraperitoneal injections of S100A12 confer
adverse effects on the offspring by increasing the rate of neonatal mortality and by

36
decreasing the weight of surviving pups (Figure 14), suggesting the mechanism by
which sterile inflammation at the maternal-fetal interface can lead to fetal/ neonatal
injury. Further studies are needed to assess the physiological relevance of S100A12 in
women who undergo premature labor.
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CHAPTER 4 - MONOSODIUM URATE INDUCES STERILE INFLAMMATION AT THE
MATERNAL-FETAL INTERFACE
Introduction
Uric acid or urate is the final product of purine metabolism that, due to its limited
solubility in bodily fluids, forms triclinic monosodium urate (MSU) crystals when present
at high concentration by bonding to one sodium and one water molecule (159).
Accumulation of MSU crystals is a well-known etiology of a form of arthritis known as
gout and is also associated with the metabolic syndrome (160).

In pregnancy,

increased uric acid is associated with gestational hypertension and preeclampsia (161164). Maternal hyperuricemia in pregnant women is also significantly associated with
preterm and small-for-gestational-age delivery (165), while amniotic fluid urate
concentrations are inversely proportional to infant birth weight (166), and serum uric
acid levels are elevated in adolescents born prematurely when compared to those born
at term (167).
High risk pregnancies are characterized by increased levels of both IL-1β and
several alarmins, such as HMGB1 and MSU, in gestational tissues as well as
systemically (168). We hypothesize that alarmins, including MSU, promote secretion of
mature IL-1β by inflammasome activation. MSU is a known activator of the NLRP3
inflammasome in T cells (169), macrophages (170, 171), dendritic cells (172), and other
immune and non-immune cell types (173-175).

Dr. Vikki M. Abrahams’ group has

demonstrated that human trophoblasts, or specialized cells of placenta, respond to uric
acid with inflammasome-dependent IL-1β production (176). More recently, Dr. Sylvie
Girard’s lab exhibited preliminary findings at the Society for Reproductive Investigations
63rd Annual Scientific Meeting suggesting that uric acid induces fetal growth restriction
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in a rat model of non-infectious inflammation during pregnancy. We aimed to determine
whether MSU is capable of inducing sterile inflammation at the maternal-fetal interface
and whether it confers any negative perinatal outcome.
Materials and Methods
Study population
The chorioamniotic membranes were obtained from women who underwent term
delivery without labor as described in Chapter 2. The demographical characteristics of
the patients are summarized in Table 4.
Table 4: Demographic characteristics of the patients whose samples were used for the
MSU study.
Age (years)
Body mass index (kg/m2)
Gestational age at delivery (weeks)
Newborn weight (g)
Race
African-American
Caucasian

26.6 (22-38)
29.1 (22.5-40.6)
39.1 (38.1-39.9)
3279 (2260-4060)

94% (16/17)
6% (1/17)
6% (1/17)
Primiparity
100% (17/17)
C-section
100% (17/17)
Absence of chorioamnionitis
Age, body mass index, gestational age at delivery, and newborn
weight are shown as mean (min-max). Race, Primiparity, Csection, and absence of chorioamnionitis are shown as percent
(positive/total).

In vitro MSU treatment
The chorioamniotic membrane explants were cultured as described in Chapter 2.
For MSU treatment, the media was supplemented with 50μg/mL of MSU (Catalog no.
Catalog # tlrl-msu, InvivoGen, San Diego, California, USA). This concentration was
chosen based on the previous dose-response experiments and the MSU/ uric acid
concentrations used by other research groups (176-179). Additionally, previous studies
showed that MSU concentrations below 400μg/mL do not affect cell viability measured
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after 24 hours, 48 hours, and 72 hours of treatment (177).
ELISA/ RT-PCR/ Immunoblotting/ Trichromic staining/ Zymogrpahy
ELISA,

RT-PCR,

immunoblotting,

trichromic

staining,

and

zymography

experiments were performed as described in Chapter 2.
Animals and husbandry/ MSU intraperitoneal injections
Animal husbandry was performed as described in Chapter 3.

S100A12 was

injected intraperitoneally at 16.5dpc at a concentration of 50μg/ml.
Statistical analysis
Statistical analysis was performed as described in Chapter 3.
Results
MSU induces the release of mature IL-1β from the chorioamniotic membranes
To determine whether MSU is capable of inducing IL-1β-dependent sterile
inflammation, we measured the expression of IL-1β both on mRNA and protein level.
We found that, although MSU only tends to up-regulate IL1B gene expression, it
Mature IL-1 

15

1150

10

1000
800

Secretion (pg/mL)

Expression (-CT)

IL1B

5

0

P=0.02

600
400
200
50
25

-5

0

Control

MSU

Control

Figure 15: MSU induces
the release of mature IL1β
from
the
chorioamniotic
membranes. Expression
of IL1B and release of
mature IL-1β from the
chorioamniotic
membranes treated with
MSU
(50μg/mL)
was
determined by RT-PCR
and ELISA, respectively.

MSU

significantly increases the release of mature IL-1β protein from the chorioamniotic
membranes (Figure 15). Interestingly, a great variability in response was seen, with
some cases exhibiting over 20-fold increase in IL-1β secretion, while others showing
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only minor change. Such a great variability in response was not observed for other
alarmins that we tested (Chapters 2, 3, & 5), which suggests that pro-inflammatory
effect of MSU is more dependent on the tissue micro-environment.
MSU up-regulates the expression of inflammasome components in the
chorioamniotic membranes
Because of release of mature IL-1β requires proteolytic processing by the
inflammasome-dependent caspase-1, we next aimed to determine whether MSU affects
expression of the inflammasome components NLRP1, NLRP3, AIM2, and NLRC4. We
found that NLRP1 (p=0.025) and NLRP3 (p=0.045) genes were significantly upregulated by the MSU treatment (Figure 16).
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Figure 16: MSU induces the release of mature IL-1β from the chorioamniotic membranes.
Expression of IL1B and release of mature IL-1β from the chorioamniotic membranes treated with
MSU (50μg/mL) was determined by RT-PCR and ELISA, respectively.
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MSU promotes activation of caspase-1 in the chorioamniotic membranes
The up-regulation of the inflammasome components NLRP1 and NLRP3
suggests that MSU is capable of activating caspase-1 in the chorioamniotic
membranes. To test whether this is the case, we performed RT-PCR, ELISA, and
Western blot to determine the levels of mRNA, total protein, and active forms of
caspase-1, respectively.
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Figure 17: MSU increases concentration of active caspase-1 in the chorioamniotic
membranes. Chorioamniotic membranes treated with MSU (50μg/mL) were subjected to RTPCR to determine expression of the CASP1 gene (A), to ELISA to evaluate the concentration of
total caspase-1 protein (B) and to immunoblotting to detect mature forms (p-10 and p-20) of
caspase-1 (C).

We found that MSU tends to increase CASP1 gene expression (Figure 17A) and
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significantly elevates the concentration of total caspase-1 protein (p<0.01) in the
chorioamniotic membranes (Figure 17B).

When we evaluated the mature forms of

caspase-1, we found that both caspase-1 p-20 (p<0.01) and caspase-1 p10 (p<0.01)
are significantly elevated after MSU treatment (Figure 17C). This suggests that MSU is
capable of inducing inflammasome-regulated caspase-1 activation and subsequent IL1β release from the chorioamniotic membranes.
MSU up-regulates expression of pro-inflammatory mediators IL6, IFNG, HMGB1,
and TLR2
Next, we assayed the expression of multiple pro-inflammatory targets upon MSU
treatment to determine the extent to which MSU propagates sterile inflammation and the
molecular pathways involved. We found that, in addition to IL-1β, MSU promotes gene
expression of two other pro-inflammatory cytokines: IL-6 (p=0.07) and IFNγ (p=0.04)
(Figure 18). Interestingly, MSU also promotes expression of another alarmin – HMGB1
(p=0.04) and its particle recognition receptor TLR2 (p=0.07) (Figure 18). As discussed
in Chapter 2, HMGB1 is a potent pro-inflammatory agent of its own. This suggests that
MSU propagates inflammation, in part, by activating HMGB1-dependent proinflammatory response. Under physiological conditions of sterile inflammation due to
tissue stress or injury, multiple alarmins are released simultaneously from the activated
leukocytes by active secretion or from the dying somatic cells by passive release.
Therefore, it is plausible that various alarmins work synergistically to promote the single
outcome – activation of the immune system required for healing.
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Figure 18: MSU up-regulates expression of pro-inflammatory mediators in the
chorioamniotic membranes. Chorioamniotic membranes treated with MSU (50μg/mL)
exhibited increased expression of IL6, IFNG, HMGB1, and TLR2.

MSU activates MMP2 and up-regulates expression of PTGS2
Next we aimed to determine whether MSU-induced inflammation leads to
establishment of pro-labor microenvironment. We found that MSU significantly actives
matrix-remodeling enzyme MMP2 (p=0.01) (Figure 19A) and collagen integrity tended to
decrease as observed using the trichrome staining (Figure 19C). In addition, MSU
upregulated expression of PTGS2 (p=0.05) (Figure 19B), which is an important enzyme
in prostaglandin biosynthesis. Therefore, MSU seems to promote remodeling of the
chorioamniotic membranes and establishment of the pro-labor environment at the
maternal-fetal interface.
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Figure 19: MSU activates MMP2 and up-regulates expression of PTGS2. Chorioamniotic
membranes treated with MSU (50μg/mL) were subjected to zymography to determine MMP2
activity (A), to RT-PCR to assess PTGS2 gene expression (B), and to trichrome staining to
visualize collagen distribution (C).

Intraperitoneal HMGB1 injections do not cause adverse neonatal outcomes
Finally, we aimed to determine whether MSU injections can induce adverse
perinatal outcome in a murine animal model.

Based on our findings that neither

HMGB1 nor S100A12 induces preterm birth when injected intraperitoneally, we
hypothesized that intraperitoneal injections of MSU may not cause preterm labor but
may have adverse effects on the neonates. However, we found that neither the rate of
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neonatal mortality nor the weights of pups changed with the administration of MSU at
16.5dpc (Figure 20). Therefore, a single intraperitoneal injection of MSU at 16.5dpc
does not cause adverse perinatal outcomes.
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Figure 20: Intraperitoneal injection of MSU does not cause adverse neonatal outcomes.
Pregnant dams were injected intraperitoneally with 100ug/mL of MSU at 16.5dpc. After delivery,
the neonates were monitored for survival and weight gain.

Discussion
Major findings of the study
The major findings of this study are:

1) MSU promotes expression and/or

secretion of pro-inflammatory cytokines including IL-1β, IL-6, and IFNγ in the
chorioamniotic membranes; 2) MSU significantly up-regulates gene expression of the
inflammasome components NLRP1 and NLRP3; 3) MSU increases concentration of
pro- and active forms of caspase-1; 4) MSU promotes MMP2 activity and collagen
remodeling of the chorioamniotic membranes and up-regulates PTGS2 gene
expression; 5) A single intraperitoneal injection of MSU at 16.5 dpc does not cause
adverse perinatal outcomes in a mouse model.
MSU promotes sterile inflammation of the chorioamniotic membranes
We found that MSU is capable of inciting sterile inflammation of the
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chorioamniotic membranes via up-regulation of pro-inflammatory cytokines, most
notably IL-1β (Figure 15 & 18). The increased secretion of mature IL-1β coincided with
up-regulation of two inflammasome components – NLRP1 and NLRP3 (Figure 16) and
elevated concentration of inflammasome-activated caspase-1 (Figure 17). Interestingly,
we showed that NLRP3 expression in the chorioamniotic membranes gets up-regulated
in vitro by three alarmins tested by us: HMGB1 (Figure 4), S100A12 (Figure 9), and
MSU (Figure 16). Preterm labor is a syndrome associated with multiple pathological
processes (8) which eventually converge on the common final pathway of parturition
(180). The NLRP3 inflammasome may respond to the various pathological signals at
the maternal-fetal interface and initiate pro-inflammatory cascade that ultimately leads
to labor.

The sequential activation of the inflammasome and caspase-1 leading to

release of IL-1β was proposed previously as a candidate pathway towards parturition
when the amniotic fluid concentration of caspase-1 was found to be elevated in term
labor and in preterm labor with intraamniotic infection/inflammation (41). Our current
findings support this hypothesis and provide a mechanism by which multiple stimuli can
incite the inflammasome-regulated IL-1β release.
MSU promotes pro-labor environment but fails to induce adverse perinatal
outcomes
We hypothesized that sterile inflammation incited by MSU can promote preterm
labor. We found that MSU-induced pro-inflammatory signaling indeed coincided with
increased activity of extracellular matrix remodeling enzyme MMP2 as well as with
collagen rearrangement and increased expression of prostaglandin synthase PTGS2
(Figure 19). However, these in vitro observations did not coincide with any adverse
perinatal effects in vivo (Figure 20). This discrepancy may be due to insufficient in vivo
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stimulation at the maternal-fetal interface, since a single 100mg/ml injection was
performed intraperitoneally rather than intraamniotically. A rat model of non-infectious
inflammation during pregnancy that involved consecutive injections of MSU crystals
from gestation day 18 to 21 (250, 500, or 1000mg/kg/12hr) reportedly resulted in fetal
growth restriction (Dr. Sylvie Girard’s lab, data not published). Since urate is a normal
product of purine metabolism and is normally found in the amniotic fluid, higher doses
may be required to elicit pro-inflammatory response strong enough to induce preterm
birth and/or other perinatal complications. Serial injections with higher concentration of
MSU will have to be performed in order to better analyze the effect of this alarmin on
gestation and fetal/neonatal health.

48
CHAPTER 5 - HEAT SHOCK PROTEIN 70 INDUCES STERILE INFLAMMATION AT
THE MATERNAL-FETAL INTERFACE
Introduction
70-kDa heat shock proteins (HSP70s) are folding catalysts and molecular
chaperones (181) that are thought to act as alarmins when released extracellularly (182,
183).

HSP70 proteins are associated with numerous disorders characterized by

pathological inflammation including inflammatory bowel disease (184), stroke (185),
chronic kidney disease (186), cancer (187), and others (188-190).

In pregnancy,

elevated HSP70 levels in the amniotic fluid correlate with term labor and spontaneous
preterm labor with premature rupture of membranes and intraamniotic infection/
inflammation (191).

Increased HSP70 in the maternal and fetal circulations is also

associated with preterm delivery (192).

Finally, increased placental expression of

HSP70 is associated with preterm birth and/or low birth weights (193).
However, anti-inflammatory effects of HSP70 have been reported as well (194196). For instance, vaginal HSP70 protein expression in mid trimester pregnant women
is associated with the downregulation of the pro-inflammatory immune response to
abnormal vaginal flora (197). A paper by Eden et al. (198) even proposes to reclassify
heat shock proteins as “DAMPERs” rather than DAMPs because of their tendency to
dampen the inflammation.

Recently, a hypothesis was proposed asserting that

extracellular to intracellular HSP70 ratio determines pro- vs anti-inflammatory action of
this protein (199). We aimed to ascertain whether HSP70 acts as an alarmin at the
maternal-fetal interface. Based on our findings with other DAMPs (Chapters 2 through
4), we specifically hypothesized that HSP70 is capable of inducing inflammasomedependent, caspase-1-mediated release of IL-1β as well as other pro-inflammatory
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cytokines from the chorioamniotic membranes, which leads to perinatal complications in
an animal model.
Materials and Methods
Study population
The chorioamniotic membranes were obtained from women who underwent term
delivery without labor as described in Chapter 2. The demographical characteristics of
the patients are summarized in Table 5.
Table 5: Demographic characteristics of the patients whose samples were used for the
HSP70 study
28.5 (20-36)
Age (years)
33 (20.4-50.6)
Body mass index (kg/m2)
39.1 (37-41.9)
Gestational age at delivery (weeks)
3341 (2740-3820)
Newborn weight (g)
Race
African-American
90.5% (19/21)
Caucasian
9.5% (2/21)
9.5% (2/21)
Primiparity
100% (23/23)
C-section
95.2% (20/21)
Absence of chorioamnionitis
Age, body mass index, gestational age at delivery, and newborn
weight are shown as mean (min-max). Race, Primiparity, Csection, and absence of chorioamnionitis are shown as percent
(positive/total).

In vitro HSP70 treatment
The chorioamniotic membrane explants were cultured as described in Chapter 2.
For HSP70 treatment, the media was supplemented with 10μg/mL of full-length HSP70
(Catalog no. ab78434, Abcam). Injury-induced lysis of as little as a half a gram of tissue
could cause extracellular release of 100μg/mL of HSP70 (200). The concentration that
we chose for the in vitro treatment was lower or in line with the published studies from
several research groups (200-204).
ELISA/ RT-PCR/ Immunoblotting/Trichromic staining/Statistical methods
ELISA, RT-PCR, immunoblotting, and trichromic staining experiments were
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performed as described in Chapter 2. Statistical methods were described in Chapter 3.
Animals and husbandry/ HSP70 Intraperitoneal injections
Animal were handled and injected as described in Chapter 3. Concentration of
20μg/ml was used for the intraperitoneal injections.
Results
HSP70 induces the release of mature IL-1β from the chorioamniotic membranes
To determine whether HSP70 can exert pro-inflammatory effect on the
chorioamniotic membranes, the membrane explants cultured with recombinant HSP70
were subjected to RT-PCR and ELISA to determine expression of IL1B gene and
secretion of mature IL-1β protein, respectively. We found that, although HSP70 did not
change expression of IL1B, it significantly up-regulated IL-1β protein secretion
(p<0.001) (Figure 21). This finding supports the assertion that HSP70 is an alarmin that
initiates pro-inflammatory signaling.
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Figure 21: HSP70 induces release of mature IL-1β from the chorioamniotic membranes.
Chorioamniotic membrane explants treated with HSP70 (10μg/mL) were subjected to RT-PCR
to determine expression of IL1B and to ELISA to measure concentration of mature IL-1β
released into the media.
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HSP70 promotes activation of caspase-1
To determine whether the observed increase of IL-1β upon HSP70 treatment
occurs via activation of the caspase-1 enzyme, we measured CASP1 gene expression,
concentration of total caspase-1 protein as well as pro- and active forms of caspase-1.
We found that HSP70 does not significantly affect the gene expression of CASP1
(Figure 22A) and the concentration of total caspase-1 protein (Figure 22B), yet it does
promote activation of caspase-1 as confirmed by the increased immunoreactivity of
caspase-1 p20 (p<0.01) after HSP70 treatment (Figure 22C). Thus, HSP70 promotes
activation, but not transcription, of caspase-1.
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Figure 22: HSP70 promotes activation of caspase-1 in the chorioamniotic membranes.
Chorioamniotic membranes treated with HSP70 (10μg/mL) were assayed for expression of
CASP1 gene by RT-PCR (A), concentration of total caspase-1 protein by ELISA (B), and the
presence of active forms of caspase-1 by Western blot (C).
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HSP70 does not induce expression of the major inflammasome components
Because inflammasome complexes are known to activate caspase-1, we next
aimed to determine whether increased activity of caspase-1 after HSP70 treatment
corresponds to up-regulation of the inflammasome components. We found that neither
one of the four inflammasome components tested (AIM2, NLRP1, NLRP3, and NLRC4)
was up-regulated in response to HSP70 (Figure 23). In fact, HSP70 tended to downregulate these genes.
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Figure 23: HSP70 does not induce expression of the major inflammasome components in
the chorioamniotic membranes. Chorioamniotic membranes treated with HSP70 (10μg/mL)
were assayed for expression of AIM2, NLRP1, NLRP3, and NLRC4 by RT-PCR.
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This surprising finding suggests that HSP70 either induces inflammasome
assembly rather than the expression of inflammasome components or promotes
activation of caspase-1 via inflammasome-independent signaling.
HSP70 increases expression of NOD2 and TNF
To further determine the extent of HSP70-induced sterile inflammation, we
assayed the expression of the NOD proteins (NOD1 and NOD2), the pro-inflammatory
transcription factor (NFKB1), and its down-stream targets TNF, IL6, IL1A, IFNG, and
IL18).
We found that HSP70 significantly up-regulated TNF (p=0.01) and tended to upregulate NOD2 (p=0.06) (Figure 24). Therefore, HSP70 does not seem to induce strong
pro-inflammatory transcriptional response in the chorioamniotic membranes.
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Figure 24: HSP70 increases expression of NOD2 and TNF in the chorioamniotic
membranes. The chorioamniotic membranes treated with HSP70 (10μg/mL) were subjected to
RT-PCR to determine expression of NOD2 and TNF, but not of NOD1, NFKB1, IL6, IL1A, IFNG,
or IL18.
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HSP70 up-regulates expression of MMP9 in the chorioamniotic membranes
Although HSP70 seemed to elicit weaker pro-inflammatory response compared
to the other alarmins that we tested (Chapters 2 through 4), we aimed to determine
whether HSP70-stimulated release of mature IL-1β is able to induce membrane
remodeling and establish pro-labor environment in the chorioamniotic membranes.
We found that HSP70 significantly upregulated expression of MMP9 (p=0.018),
but not of PTGS2 (Figure 25A). Trichromic staining suggested that HSP70 promotes
collagen reorganization of the chorioamniotic membranes (Figure 25B).

Figure 25: HSP70 up-regulates expression of MMP9 and remodels collagen composition
of the chorioamniotic membranes. The chorioamniotic membranes treated with HSP70
(10μg/ml) exhibited increased expression of MMP9 (A) and collagen remodeling (B).
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HSP70 increases neonatal mortality in vivo
Finally, to determine whether HSP70 has adverse perinatal effects, pregnant
mice were administered HSP70 via intraperitoneal injection at 16.5dpc. Although, no
preterm birth was observed (data not shown), the neonatal mortality rate significantly
increased (p<0.001), while pup weights were not affected (Figure 26).

Thus,

intraperitoneal administration of HSP70 promotes neonatal mortality in vivo.
P<0.001
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Figure 26: HSP70 increases neonatal mortality in vivo. Damps were injected
intraperitoneally with HSP70 (20μg/mL) at 16.5dpc. After term delivery, neonatal mortality and
pup weights were recorded.

Discussion
Major findings
The major findings of this study are: 1) HSP70 significantly increases secretion
of mature IL-1β from the chorioamniotic membranes; 2) Although HSP70 does not upregulate expression of the inflammasome components, it does promote activation of
caspase-1; 3) HSP70 upregulates expression of the pro-inflammatory cytokine TNF and
the matrix remodeling enzyme MMP9; 4) Intraperitoneal injection of HSP70 at 16.5dpc
greatly increases the rate of neonatal mortality.
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HSP70 promotes maturation of IL-1β by caspase-1
The findings herein show that HSP70 significantly increases the release of
mature IL-1β from the chorioamniotic membranes (Figure 21) and simultaneously
promotes activation of the IL-1β cleaving enzyme caspase-1 (Figure 22). However,
HSP70 does not increase the expression of the inflammasome components that we
tested (Figure 23). Inflammasome activation is a two-step process that requires both
priming and assembly of the inflammasome complex (92, 93).

The priming step

involves NFκB-directed transcriptional up-regulation of the inflammasome components
to a functional level (91-93). The second step is post-transcriptional and allows the
assembly of the NLRP3 inflammasome complex (92, 93).

Considering that treatment

with HSP70 did not up-regulate expression of NFκB and its downstream targets, with an
exception of TNF (Figure 24), it is possible that HSP70 acts at the second step of
inflammasome activation by promoting assembly of the inflammasome complex. To
test this possibility, additional experiments that assess the inflammasome assembly will
have to be performed. It is also possible that HSP70 promotes secretion of IL-1β via
inflammasome-independent pathway. Several such pathways have been described in
the literature (105, 205-208) and inflammasome/caspase-1-independent processing of
IL-1β is an area of active research. Further research is required to determine if and
what inflammasome-independent pathways are involved in HSP70-stimulated secretion
of IL-1β at the maternal-fetal interface.
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CHAPTER 6 - INVARIANT NKT CELL ACTIVATION INDUCES LATE PRETERM
BIRTH THAT IS ATTENUATED BY ROSIGLITAZONE
(This chapter contains previously published material. See Appendix C)
Introduction
Administration of such alarmins as IL1α (112) or HMGB1 (209) induces preterm
labor/birth. In addition, IL33, a classic alarmin (102), is expressed in decidual tissues
and up-regulated in acute chorioamnionitis (210), a placental lesion associated with
preterm labor (211). Recently, it was demonstrated that IL33 is a potent activator of
invariant (i)NKT cells (212, 213). Therefore, we hypothesized that activation of iNKT
cells, immune cells that can be activated by alarmins in the context of sterile
inflammation, could participate in the immune mechanisms that lead to non-infectionrelated preterm labor/birth.
iNKT-cell activation induces the initiation of signaling pathways (e.g., the NF-κΒ
pathway) that lead to the production of Th1 and Th2 cytokines and chemokines (214219) which, in turn, leads to a massive immune response mediated by innate and
adaptive immune cells (220). Hence, we hypothesized that iNKT-cell activation via αgalactosylceramide (α-GalCer), a high affinity iNKT ligand (221, 222), would activate
innate and adaptive immune cells at the maternal-fetal interface promoting pathological
inflammation and leading to spontaneous preterm labor/birth. In addition, we proposed
that suppression of this inflammatory response would prevent PTB induced by NKT-cell
activation.

In search of an anti-inflammatory drug to prevent PTB, we evaluated

rosiglitazone, a selective peroxisome proliferator-activated receptor (PPAR)γ agonist
(223).

Rosiglitazone causes activation of the PPARγ pathway which, in turn,

suppresses gene transcription by interfering with signal transduction pathways, such as
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the NF-κB, STAT, and AP-1 pathways (224-226).

PPARγ activation has been

suggested as a therapeutic intervention for preventing PTB (227) since treatment with
15-deoxy-∆12,14-prostaglandin J2 compound, a PPARγ agonist (228, 229), delays
endotoxin-induced PTB (230).

However, whether PPARγ activation blunts the

inflammatory response induced by iNKT-cell activation has not been investigated.
Using a murine model, our investigations demonstrate for the first time that
administration of α-GalCer in the third trimester leads to late PTB, which is prevented
following PPARγ activation by treatment with rosiglitazone. In addition, we describe that
PPARγ activation regulates immune mechanisms locally, at the maternal-fetal interface,
and systemically to attenuate α-GalCer-induced late PTB.

Finally, we broaden the

significance of our findings by demonstrating an increase of activated iNKT-like cells in
decidual tissue from women who underwent spontaneous preterm labor/birth.
Materials and Methods
Animals
C57BL/6J (B6) mice were bred in the animal care facility at the C.S. Mott Center
for Human Growth and Development at Wayne State University, Detroit, Michigan,
USA, and housed under a circadian cycle (light: dark=12:12 h). Eight- to 12-week-old
females were mated with male mice of proven fertility. Female mice were examined
daily between 8:00 a.m. and 9:00 a.m. for the presence of a vaginal plug, which
denoted 0.5 days post-coitum (dpc). Upon observation of vaginal plugs, female mice
were then separated from the males and housed in other cages. The weight gain of two
or more grams confirmed pregnancy at 12.5 dpc. Procedures were approved by the
Institutional Animal Care and Use Committee (IACUC) at Wayne State University.
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α-GalCer-induced late preterm birth model
Pregnant B6 mice were i.v. injected with 1µg, 2µg, 3µg, or 4µg of α-GalCer
(KRN7000, Funakoshi Co., Ltd., Tokyo, Japan; n=3 each for 1µg, 3µg, or 4μg, and n=20
for 2μg) that had been dissolved in 50µl of 4% DMSO (Sigma-Aldrich Co., LLC, St.
Louis, MO, USA) or with 50µl of 4% DMSO alone (referred to throughout the manuscript
as DMSO) as a control (n=19) at 16.5 dpc (third trimester).

Following injection,

pregnant mice were monitored using a video camera with infrared light (Sony
Corporation, China) until delivery. A second group of mice was i.v. injected with either
2μg of α-GalCer or DMSO at 10.5 dpc (n=5 each; second trimester), and inspection of
resorption sites was performed at 14.5 dpc. A third group of mice was i.v. injected with
2μg of α-GalCer at 10.5 dpc (n=3) and monitored during delivery; photographs of the
neonates at 1 day and 2 days after birth were taken using a camera (Sony).
Video monitoring, pup mortality and neonatal weight
Video monitoring allowed for determination of gestational age and rate of pup
mortality. Gestational age was calculated from the presence of the vaginal plug (0.5
dpc) until the observation of the first pup in the cage bedding. The rate of pup mortality
for each litter was defined as the proportion of born pups found dead among the total
litter size. Late PTB was defined as delivery between 18.0 and 18.5 dpc. Neonatal
survival and weight were recorded after one week postpartum.
In vivo imaging by ultrasound
On the morning of 16.5 dpc, pregnant B6 mice were anesthetized by inhalation of
2-3% isoflurane (Aerrane, Baxter Healthcare Corporation, Deerfield, IL, USA) and 1-2
L/min of oxygen in an induction chamber. Using Doppler ultrasound, the fetal heart rate
and umbilical artery hemodynamic parameters were recorded (VisualSonics Inc.,
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Toronto, ON, Canada). Following ultrasound, dams were placed under a heat lamp for
recovery, which occurred 10-20 min after heating. On the same day at noon, dams
were injected either with 2μg of α-GalCer or DMSO as described previously (n=3 each).
On the afternoon of 17.5 dpc (just prior to late PTB in those mice injected with αGalCer), a second ultrasound was performed, and the same hemodynamic parameters
were evaluated.
Video monitoring by infrared thermography
Pregnant B6 mice were i.v injected with 2μg of α-GalCer at 16.5 dpc (n=3).
Immediately after late preterm delivery, the body temperature of the newborns was
monitored using a thermal infrared camera (FLIR e50, FLIR Systems, Inc., Wilsonville,
OR, USA). Temperature readings were recorded at intervals of 15 and 30 sec, and also
at intervals of 1, 2, 3.5, 5.5, and 8 min after birth. A newborn that maintained a constant
body temperature was considered a viable pup, while a newborn that gradually
decreased in body temperature to the level of room temperature was qualified as a
dead pup; viable and dead pups were also confirmed by visual analysis.
Fetal and placental weights
Pregnant B6 mice were i.v. injected with 2μg of α-GalCer (n=8) or DMSO (n=6)
at 16.5 dpc. Six hours after injection, dams were euthanized, and placental and fetal
weights were recorded using a scale (DIA-20, American Weight Scales, Norcross, GA,
USA).
Rosiglitazone treatment of α-GalCer-induced late PTB
Pregnant B6 mice were i.v. injected with 2µg of α-GalCer (n=14) at 16.5 dpc.
After 2h, mice were s.c. injected with a 10mg/kg of body weight dose of rosiglitazone
(Selleck Chemicals, Houston, TX, USA) diluted in 1:10 DMSO. Control pregnant mice
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received only the dose of rosiglitazone at 16.5 dpc (n=10). Following injection, mice
were monitored via video camera with infrared light until delivery (Figure 2A).
Tissue collection from pregnant mice
Pregnant B6 mice were i.v. and/or s.c. injected at 16.5 dpc with: 1) DMSO, 2)
2μg of α-GalCer, 3) 2μg of α-GalCer followed by rosiglitazone (10mg/kg of bodyweight)
2h after, or 4) rosiglitazone alone as a control. Mice were euthanized 6h after the
injection with α-GalCer or DMSO, or 4h after treatment with rosiglitazone (n=6-10 mice
per group). Decidual and myometrial tissues from one implantation site were collected
as previously described (231) and placed in RNAlater Stabilization Solution (Life
Technologies, Grand Island, NY, USA) according to the manufacturer’s instructions.
Decidual and myometrial tissues from the remaining implantation sites were collected,
and leukocytes were immediately isolated. The spleen, uterine lymph nodes (ULN), and
liver were also collected, and leukocyte suspensions were prepared.
Leukocyte isolation from murine tissues
Isolation of leukocytes from myometrial and decidual tissues was performed as
previously described (231).

Briefly, tissues were cut into small pieces using fine

scissors and enzymatically digested with StemPro Cell Dissociation Reagent (Accutase,
Life Technologies) for 35 min at 37°C. The spleen, ULN, and liver were gently
dissociated using two glass slides in order to prepare a single leukocyte suspension.
Leukocyte suspensions were filtered using a 100µm cell strainer (Fisher Scientific,
Hanover Park, IL, USA), and washed with FACS buffer [0.1% bovine serum albumin
(Sigma-Aldrich) and 0.05% sodium azide (Fisher Scientific Chemicals, Fair Lawn, NJ,
USA) in 1X PBS (Fisher Scientific Bioreagents)] before immunophenotyping.
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Immunophenotyping of murine leukocytes
Leukocyte suspensions from decidual and myometrial tissues and the liver were
stained using the LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Life Technologies) prior
to incubation with extracellular mAbs. Leukocyte suspensions were then centrifuged,
and cell pellets were incubated for 10 min with the CD16/CD32 mAb (FcγIII/II Receptor;
BD Biosciences, San Jose, CA, USA), and subsequently incubated with specific
fluorochrome-conjugated anti-mouse mAbs (Table 6) for 30 min.

Leukocyte

suspensions were lysed/fixed with Lyse/Fix Buffer (BD Biosciences) for extracellular
staining, and the BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit (BD
Biosciences) for intracellular staining. At least 50,000 events for the spleen, liver, and
decidual cells, or 25,000 events for the ULN and myometrial cells, were acquired using
the BD LSRFortessa flow cytometer (BD Biosciences) and the FACSDiva 8.0 software
(BD Biosciences).

Leukocyte subsets were gated within the viability gate.

Immunophenotyping included identification of: 1) CD1d-restricted iNKT cells (CD1d
Tetramer+DX5+NK1.1+TCRβ+ cells) and their activation status by expression of CD69,
CD44, IFNγ, and IL4; 2) conventional T cells (CD3+CD4+ and CD3+CD8+ cells) and their
activation status by expression of CD69, CD25, PD1, CD40L, and CTLA-4; 3)
neutrophils (CD11b+Ly6G+ cells) and their activation status by expression of IFNγ; 4)
macrophages (CD11b+F4/80+ cells) and their activation status by expression of Arg1,
iNOS,

IFNγ,

and

IL10;

and

(CD11b+CD11c+DEC205+ cells).

5)

expression

of

IFNγ

by

mature

DCs

Data were analyzed using the FACSDiva 8.0

software. The total number of specific leukocytes was determined using CountBright
absolute counting beads (Molecular Probes, Eugene, OR, USA).

The figures were

prepared using the FlowJo Software version 10 (FlowJo, LLC, Ashland, OR, USA).
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Table 6: List of antibodies used for Flow Cytometry analysis for the iNKT study
Antibody

Fluorochrome

Clone

Catalog #

Company

CD3ε

APC-Cy7 or PE-Cy5

145-2C11

557596/553065

BD Biosciences

CD4

APC or AF 700

RM4-5

553051/561025

BD Biosciences

CD8

PE-CF594 or PE-Cy5

53-6.7

562283/561094

BD Biosciences

CD25

PE-Cy7

PC61

552880

BD Biosciences

CD154/CD40L

APC

MR1

17-1541-82

eBioscience

CD279/PD-1

FITC

J43

11-9985-85

eBioscience

CD69

PE-CF594

H1.2F3

562455

BD Biosciences

CD152/CTLA-4

PE

UC10-4F10-11

561718

BD Biosciences

CD11b

PE-CF594

M1/70

562287

BD Biosciences

Ly6G

APC

1A8

560599

BD Biosciecnces

F4/80

APC-efluor 780

BM8

47-4801-82

eBioscience

iNOS

PE

CXNFT

12-5920-82

eBioscience

IL4

PE-Cy7

11B11

560699

BD Biosciences

IFNγ

V450

XMG1.2

560661

BD Biosciences

CD49b/DX5

APC

DX5

560628

BD Biosciences

NK1.1

AF 700

PK136

560515

BD Biosciences

TCR-β

PerCP-Cy 5.5

H57-597

560657

BD Biosciences

CD44

APC-Cy7

IM7

560568

BD Biosciences

CD11c

AF488

N418

53-0114-82

eBioscience

DEC205

PerCP-eFluor 710

205yekta

46-2051-82

eBioscience

IL-10

AF700

JES5-16E3

56-7101-82

eBioscience

CD16/CD32

N/A

2.4G2

553142

BD Biosciences

CD1d Tetramer
NIH
PE
N/A
N/A
loaded with α-Galcer
Antibody name, the directly conjugated flourochrome, clone, catalog number, and company are listed.

Gene expression determination
RNA was extracted from decidual and myometrial tissues using TRIzol Reagent
(Life Technologies), QIAshredders (Qiagen, Valencia, CA, USA), RNase-Free DNase
Sets (Qiagen), and RNeasy Mini Kits (Qiagen). RNA concentrations and purity were
assessed with the NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington,
DE, USA), and RNA integrity was evaluated with the Bioanalyzer 2100 (Agilent
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Technologies, Wilmington, DE, USA). cDNA was synthesized using RT2 First Strand
Kits (Qiagen).
The RT² Profiler Mouse PPAR Targets PCR Array (Qiagen) and RT² Profiler
Mouse Inflammatory Cytokines & Receptors PCR Array (Qiagen) were used for initial
screening (n=4 samples per group) and performed by using RT² SYBR Green ROX
qPCR Mastermix (Qiagen) on a 7500 Fast Real-Time PCR System (Applied
Biosystems, Life Technologies Corporation, Foster City, CA, USA). Expression profiling
of those genes selected based on the screening results was confirmed by qRT-PCR
using a BioMark High-throughput qRT-PCR System (Fluidigm, San Francisco, CA,
USA) and an ABI 7500 FAST Real-Time PCR System (Applied Biosystems) using
TaqMan gene expression assays (Applied Biosystems) (n=6-8 mice per group; Table 7).
Table 7: List of primers used for RT-PCR in the iNKT study
Gene Name

Gene
Symbol

Assay ID

β-actin

Actb

Mm00607939_s1

Chemokine (C-C motif) ligand 1

Ccl1

Mm00441236_m1

Chemokine (C-C motif) ligand 12

Ccl12

Mm01617100_m1

Chemokine (C-C motif) ligand 2

Ccl2

Mm00441242_m1

Fatty acid binding protein 4

Fabp4

Mm00445878_m1

Long-chain fatty acid transport protein 4

Fatp4

Mm01327405_m1

Tumor necrosis factor α

Tnf

Mm00443258_m1

Company
Invitrogen/Applied
Biosystems
Invitrogen/Applied
Biosystems
Invitrogen/Applied
Biosystems
Invitrogen/Applied
Biosystems
Invitrogen/Applied
Biosystems
Invitrogen/Applied
Biosystems
Invitrogen/Applied
Biosystems

Gene name, gene symbol, assay ID, and company are listed.

Chemokine/cytokine serum concentrations
Pregnant B6 mice were injected at 16.5 dpc with: 1) DMSO, 2) 2μg of α-GalCer,
3) 2μg of α-GalCer followed by rosiglitazone (10mg/kg bodyweight) 2h after, or 4)
rosiglitazone alone as a control. Mice were euthanized 6h or 24h after the injection with
α-GalCer or DMSO (n=8-9 mice per group). Blood was recovered by cardiac puncture,
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and serum samples were separated by centrifugation and stored at -20°C until analysis.
The Milliplex MAP Mouse Cytokine/Chemokine Kit (MCYTOMAG-70K-PX32, EMD
Millipore, Billerica, MA, USA) was used to measure the concentrations of G-CSF, GMCSF, IFNγ, IL1α, IL1β, IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL10, IL12p40, IL12p70, IL13,
IL15, IL17, CCL11, CXCL10, CXCL1, LIF, CXCL5, CCL2, M-CSF, CXCL9, CCL3,
CCL4, CXCL2, CCL5, and TNF-α in the serum samples according to the manufacturer’s
instructions. Plates were read using the Luminex 100 System (Luminex Corporation,
Austin, TX, USA), and analyte concentrations were calculated using the xPONENT3.1
software (Luminex). The sensitivities of the assays were: 1.7pg/ml (G-CSF), 1.9pg/ml
(GM-CSF), 1.1pg/ml (IFNγ), 10.3pg/ml (IL1α), 5.4pg/ml (IL1β), 1.0pg/ml (IL2), 1.0pg/ml
(IL3), 0.4pg/ml (IL4), 1.0pg/ml (IL5), 1.1pg/ml (IL6), 1.4pg/ml (IL7), 17.3pg/ml (IL9),
2.0pg/ml (IL10), 3.9pg/ml (IL12p40), 4.8pg/ml (IL12p70), 7.8pg/ml (IL13), 7.4pg/ml
(IL15), 0.5pg/ml (IL17), 1.8pg/ml (CCL11), 0.8pg/ml (CXCL10), 2.3pg/ml (CXCL1),
1.0pg/ml (LIF), 22.1pg/ml (CXCL5), 6.7pg/ml (CCL2), 3.5pg/ml (M-CSF), 2.4pg/ml
(CXCL9), 7.7pg/ml (CCL3), 11.9pg/ml (CCL4), 30.6pg/ml (CXCL2), 2.7pg/ml (CCL5),
2.3pg/ml (TNF-α) and 0.3pg/ml (VEGF).

Inter-assay and intra-assay coefficients of

variation were below 15% and 4.9%, respectively.
Human samples
Chorioamniotic membrane and basal plate samples were collected within 30 min
after delivery from the Bank of Biological Specimens of the Perinatology Research
Branch, an intramural program of the Eunice Kennedy Shriver National Institute of Child
Health and Human Development, National Institutes of Health, U. S. Department of
Health and Human Services (NICHD/NIH/DHHS), Wayne State University, and The
Detroit Medical Center (Detroit, MI, USA). The Institutional Review Boards approved
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the collection and use of biological materials for research purposes. All participating
women provided written informed consent. The study groups included women who
delivered at term without labor (TNL), at term with labor (TIL), preterm without labor
(PTNL), and preterm with labor (PTL).

Demographic and clinical characteristics of

these study groups are represented in Table 8. Patients with multiple births or with
neonates having congenital or chromosomal abnormalities were excluded. Labor was
defined by the presence of regular uterine contractions at a frequency of at least two
contractions every 10 minutes with cervical changes resulting in delivery (232). In each
case, several tissue sections of the chorioamniotic membranes, umbilical cord, and
placental disc were evaluated for acute chorioamnionitis and chronic chorioamnionitis,
according to published criteria (233, 234), by pathologists who had been blinded to the
clinical outcome.
Table 8: Demographical characteristics of patients whose samples were used for the
iNKT study
Demographic or clinical
characteristic
Maternal age (years)*
Race**
African-American
Caucasian
Hispanic
Other
Maternal weight (kg)*
Body mass index (kg/m²)*
Primiparity**
Gestational age at
delivery (weeks)*
Birth weight (grams)*
Cesarean section**
Chronic
h i
i iti **
Acute chorioamnionitis**
Smoked during
Pregnancy**
Yes
No

TNL
(n=7)
28 (23-32)

TIL
(n=26)
23.5 (22-27)

7 (100%)
0 (0.0%)
0 (0.0%)
0 (0.0%)

26 (100%)
0 (0.0%)
0 (0.0%)
0 (0.0%)

93 (68.8-98.7)

PTL
(n=14)
22 (19.5-25)

P value

NS

0 (0.0%)
1 (7.7%)

13 (92.9%)
1 (7.1%)
0 (0.0%)
0 (0.0%)

90.05 (71.1-106.0)

74.8 (62.6-102.7)

75.6 (56.7-88.2)

NS

33.9 (27.38-39.25)

32.8 (23-39.4)

28.35 (21.53-31.6)

NS

6 (23.08%)

3 (23.08%)

1 (7.14%)

NS

39 (38.5-39.5)

39.4 (38.2-39.9)

34.9 (32-36.1)

34.2 (31.2-35.3)

<0.0001

3005 (2855-3073)

3240 (2906-3419)

1510 (1255-2375)

2148 (1674-2554)

<0.0001

100%
28.6%

15.4%
30.8%

100%
46.2%

14.3%
21.4%

<0.0001
NS

0%

34.6%

7.7%

42.8%

NS

1 (14.3%)
6 (85.7%)

5 (19.2%)
21 (80.8%)

2 (15.4%)
11 (84.6%)

0 (0%)
14 (100%)

NS

31.2 (26.3541.45)
0 (0%)

PTNL
(n=13)
25 (22-30)
11 (84.6%)
1 (7.7%)

NS

(*Kruskal-Wallis test, **Chi-square test). Maternal age, race, maternal weight, body max index, Primiparity, gestational
age at delivery, birth weight, Cesarean section, chronic chorioamnionitis, acute chorioamnionitis, smoking during
pregnancy are listed as median (interquantile range) or n (%). Either Kruskal-Wallis test or Chi-square test were used
to analyze the statistical differences between the study groups (TNL, TIL, PTNL, and PTL).
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Decidual leukocyte isolation from human samples
Decidual leukocytes from human decidual tissue were isolated as previously
described (235). Briefly, the decidua basalis was collected from the basal plate of the
placenta, and the decidua parietalis was separated from the chorioamniotic membranes
(Figure 8A).

Decidual tissue was homogenized using a gentleMACS Dissociator

(Miltenyi Biotec, San Diego, CA, USA) in StemPro Cell Dissociation Reagent.
Homogenized tissues were incubated for 45 min at 37°C with gentle agitation. After
incubation, tissues were washed in ice-cold 1X PBS (Life Technologies) and filtered
through a 100μm cell strainer. Cell suspensions were collected and centrifuged at 300
x g for 10 min, and the cell pellet was suspended in FACS buffer.

Mononuclear

leukocytes were purified using a density gradient (Ficoll-Paque Plus; GE Healthcare
Bio-Sciences AB, Sweden), following the manufacturer’s instructions.

Lastly,

mononuclear

before

cell

suspensions

were

washed

using

FACS

buffer

immunophenotyping.
Immunophenotyping of human decidual leukocytes
Mononuclear cell suspensions from decidual tissues were stained with BD
Horizon Fixable Viability Stain 510 dye (BD Biosciences) prior to incubation with
extracellular mAbs.

Mononuclear cell suspensions were then washed with staining

buffer (Cat No. 554656; BD Biosciences) and centrifuged. Cell pellets were incubated
for 10 min with FcR Blocking Reagent (Cat No. 130-059-901; Miltenyi Biotec). Next,
mononuclear cell suspensions were incubated with the following fluorochromeconjugated anti-human mAbs: CD14-BUV395 (clone MφP9; BD Biosciences), CD15BV605 (clone W6D3; BD Biosciences), CD3-BV650 (clone OKT3; BD Biosciences),
CD19-BUV737 (clone SJ25C1; BD Biosciences), CD56-PE-Cy7 (clone NCAM16.2; BD
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Biosciences), CD69-Alexa Fluor 700 (clone FN50; BD Biosciences) and Vα24Jα18TCRPE (clone 6B11; eBioscience; San Diego, CA, USA) for 30 min at 4 ºC in the dark.
Finally, mononuclear cell suspensions were washed and re-suspended in 0.5ml of
staining buffer and acquired using the BD LSRFortessa flow cytometer and FACSDiva
6.0 software. Leukocyte subsets were gated within the viability gate, and activated
iNKT-like

cells

were

identified

CD3+Vα24Jα18TCR+CD69+ cells.

as

CD15-CD14-CD19-CD3+CD56+CD69+

or

The analysis was performed, and the figures

generated using FlowJo Software version 10.
Immunofluorescence
Immediately after collection, the chorioamniotic membranes were frozen in
Tissue-Plus O.C.T. Compound (Fisher HealthCare, Houston, TX, USA). Ten-μm-thick
cryosections were cut, placed on Fisherbrand Superfrost Plus microscope slides
(Thermo Scientific, Waltham, MA, USA), fixed with 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA, USA), and washed with 1X PBS. Non-specific
antibody interaction was blocked using a Protein Blocker serum-free (Cat No. X0909;
Dako North America, Carpinteria, CA, USA) for 30 min at room temperature. Slides
were then incubated with the following anti-human mAbs: mouse CD69-FITC (LifeSpan
BioSciences, Inc., Seattle, WA, USA), mouse CD56-APC (clone MEM-188, BioLegend,
San Diego, CA, USA), and rabbit CD3 (Abcam, Cambridge, MA, USA) at 4˚C overnight.
Following incubation, slides were washed with 1X PBS containing 0.1% Tween-20
(Sigma-Aldrich). Secondary goat anti-rabbit IgG-Alexa Fluor 594 (Invitrogen, Molecular
Probes, Eugene, OR, USA) was added for CD3 detection, and slides were incubated for
1h at room temperature. Slides were washed and mounted with the ProLong Gold
Antifade reagent with DAPI (Life Technologies). Immunofluorescence was visualized
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using a Zeiss LSM 780 laser scanning confocal microscope (Carl Zeiss Microscopy
GmbH, Jena, Germany) at the Microscopy, Imaging and Cytometry Resources Core at
Wayne

State

University

School

of

Medicine

(http://micr.med.wayne.edu/).

Immunofluorescence signals for APC, Alexa Fluor 594, and FITC were excited using a
633 nm HeNe laser, a 561 nm HeNe laser, and the 488 nm line of a Multiline Argon
laser, respectively. The DAPI signal was excited using a 405 nm diode laser.
Statistical analysis
Observational mouse data were analyzed using IBM SPSS, version 19.0, and all
other analyses were performed in R (http://www.R-project.org/). For the gestational
age, rate of pup mortality, and ultrasound parameters, the statistical significance of
group comparisons was assessed using Mann-Whitney U tests. For flow cytometry
data, the statistical significance of group comparisons was assessed using MannWhitney U tests. For fetal, placental, and neonatal weights, the statistical significance
of group comparisons was assessed using pooled variance t-tests after log
transformation. For qRT-PCR arrays, negative ∆Ct values determined using multiple
reference genes (Gusb, Hsp90ab1, Gapdh and Actb) averaged within each sample to
determine gene expression levels.

A heat map was created for the group mean

expression matrix (gene x group mean) with each gene expression level being first
standardized. A hierarchical clustering tree of genes was constructed using 1-Pearson
correlation as distance metric and average linkage, while treatment groups clustering
was based on an Euclidean distance with Ward linkage. For Fluidigm qPCR assays,
negative ∆Ct values were calculated using Actb as a reference gene. For Fluidigm
gene expression and cytokine concentrations, statistical tests of group differences were
performed using linear models, and whenever data was left, right, or interval censored,
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a survival regression model with Gaussian error was used instead.

Human

demographic data were analyzed using IBM SPSS, version 19, and comparisons
among the groups were performed using Chi-square tests for proportions as well as
Kruskal-Wallis tests for non-normally distributed continuous variables. For proportions
of activated iNKT-like cells in human decidual tissues, statistical significance of group
differences was assessed using Mann-Whitney U tests. A p-value of < 0.05 was used
to determine statistical significance.
Results
α-GalCer administration in the third trimester induces late preterm birth
Intravenous administration of 2μg of α-GalCer during the third trimester caused
75±18.9% of births to be categorized as late preterm (birth occurring between 18.0 and
18.5 dpc; α-GalCer-induced late PTB), while DMSO (control) resulted in no late PTB
(Figure 27A). Consequently, dams that were i.v. injected with 2μg of α-GalCer had
shorter gestations than the DMSO control group (Figure 27B). A high proportion of
preterm pups were found dead minutes after delivery (Figure 27C).

Intravenous

administration of 3µg or 4μg of α-GalCer induced very early PTB (birth occurring before
17.5 dpc with 100% pup mortality); however, 1μg of α-GalCer did not cause PTB (data
not shown). These data demonstrate that α-GalCer administration in the third trimester
induces late PTB and pup mortality.
α-GalCer administration in the third trimester causes neonatal death
Dams that were injected with α-GalCer delivered premature viable and nonviable pups. We then investigated whether these pups were dying in the uterus (fetal
death) or after delivery (neonatal death). Abnormal umbilical artery velocimetry and
fetal heart rate are associated with fetal compromise (236-239). Therefore, Doppler
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Figure 27: α-GalCer induces late PTB but not pregnancy loss. (A) The rate of term birth was
defined as the percentage of dams delivering at 19.5 ± 0.5 dpc among all births. The rate of late
PTB was defined as the percentage of dams delivering between 18.0 and 18.5 dpc among all
births. Data are shown as percentage ± 95% confidence interval. (B) Gestational age was
calculated from the presence of the vaginal plug (0.5 dpc) until the observation of the first pup in
the cage bedding. (C) The rate of pup mortality for each litter was defined as the proportion of
born pups found dead among the total litter size. Data in (A–C) are from individual dams (n =
19–20 each). (D and E) Doppler ultrasound was performed on fetuses just prior to α-GalCer–
induced late PTB in dams injected with α-GalCer and in time-matched DMSO controls. Umbilical
artery pulsatility index and fetal heart rate were recorded. Data are from three independent
litters. (F) Immediately after α-GalCer–induced late PTB, the body temperature of the newborns
was monitored using a thermal infrared camera. Temperature readings were recorded at 0, 15,
and 30 s, as well as at 1, 2, 3.5, 5.5, and 8 min. Data are representative of individual dams (n =
3). (G) Uterine horns at 14.5 dpc from dams injected i.v. with DMSO or α-GalCer on 10.5 dpc.
Data are representative of individual dams (n = 5 each). (H) Term neonates at 1 and 2 d old
delivered from dams injected i.v. with α-GalCer on 10.5 dpc. Data are representative of
individual dams (n = 3).
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ultrasound was performed on 17.5 dpc, just prior to late PTB in those mice injected with
α-GalCer.

The umbilical artery pulsatility index did not differ between fetuses from

dams injected with α-GalCer and DMSO (Figure 27D).
However, bradycardia, a reduction of the heart rate, occurred in fetuses from
dams injected with α-GalCer when compared to the DMSO control (Figure 27E). These
data demonstrated that, although pups do not die in the uterus, their health was
compromised before birth. Administration of α-GalCer also reduced fetal and placental
weights, but did not decrease the weight of one-week-old neonates (Figure 28A-C).
A
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Fetal Weight
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Figure 28: Fetal, placental, and neonatal weights with αGalCer treatment. (A&B) Fetuses
and placentae from dams i.v. injected with 2μg of α-GalCer or DMSO were weighed 6 h postinjection. Data are pooled from 6-8 litters (n=38 for DMSO and n=58 for α-GalCer). (C)
Neonates delivered by dams i.v. injected with 2μg of α-GalCer or DMSO were weighed at 1
week postpartum. Data are from independent neonates (n=57 for DMSO and n=46 for αGalCer).

To further evaluate when the premature pups died, we placed dams injected with
α-GalCer under video surveillance using infrared thermography. A high proportion of
premature pups died within 10 min of delivery. In Figure 27F, representative frames
demonstrate that the body temperature of a non-viable premature pup (red circle)
reduced quickly from 30.5°C to 21.3°C. Conversely, a viable premature pup kept a
constant temperature of 23.3°C to 23.1°C (green circle).
α-GalCer administration in the second trimester does not cause pregnancy loss
During mid-pregnancy, iNKT-cell activation by i.p. administration of α-GalCer
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(100μg/kg of body weight, ~2.5μg) leads to pregnancy loss (240, 241). Herein, we
demonstrated that i.v. administration of 2μg of α-GalCer in the second trimester did not
cause pregnancy loss (Figure 27G). However, we could not rule out the possibility that
this dose would cause PTB or have deleterious effects on neonates.

Therefore,

neonates from dams injected with α-GalCer at 10.5 dpc were observed up to one week
post-partum. All delivered pups were viable and appeared healthy. Figure 27H shows
viable term pups at 1 day and 2 days post-partum from dams injected with α-GalCer in
the second trimester.
Rosiglitazone treatment reduces the rate of α-GalCer-induced late preterm birth
iNKT-cell activation can initiate the NF-κΒ pathway, leading to production of Th1
cytokines, such as IFNγ (216). We then hypothesized that activation of the PPARγ
pathway by administration of rosiglitazone, which interferes with the NF-κB pathway
(224, 225), would prevent α-GalCer-induced late PTB.
Dams that were injected with α-GalCer and subsequently treated with
rosiglitazone had a 40% reduction in the rate of late PTB in comparison to dams
injected with α-GalCer alone (35.7±25.1% vs. 75±18.9%; Figure 29B). Consequently,
gestational age was greater in dams treated with rosiglitazone after α-GalCer injection
than in dams injected with α-GalCer alone (Figure 29C). Importantly, dams that were
treated with rosiglitazone after an injection of α-GalCer had a 30% reduction in pup
mortality when compared to dams injected with α-GalCer alone (Figure 29D). These
results demonstrate that treatment with rosiglitazone can prevent α-GalCer-induced late
PTB and improve neonatal outcomes.
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Figure 29: Rosiglitazone treatment reduces the rate of α-GalCer–induced late PTB by
inducing PPARγ activation at the maternal–fetal interface. (A) On 16.5 dpc, pregnant mice
were injected i.v. with α-GalCer and treated shortly after with rosiglitazone (Rosi; s.c.) and
monitored via video camera (n = 14). Control mice were injected s.c. with rosiglitazone alone (n
= 10). (B) The rate of term birth was defined as the percentage of dams delivering at 19.5 ± 0.5
dpc among all births. The rate of late PTB was defined as the percentage of dams delivering
between 18.0 and 18.5 dpc among all births. Data are represented as percentage ± 95%
confidence interval. (C) Gestational age was calculated from the presence of the vaginal plug
(0.5 dpc) until the observation of the first pup in the cage bedding. (D) The rate of pup mortality
for each litter was defined as the proportion of born pups found dead among the total litter size.
(E) A heat map visualization of PPAR targets gene expression in myometrial and decidual
tissues from dams injected with DMSO, α-GalCer, Rosi, or α-GalCer + Rosi. Data are from
individual dams (n = 4 each). mRNA expression of Fabp4 (F) and Fatp4 (G) in myometrial and
decidual tissues. Negative ∆CT values (F and G) were calculated using Actb as a reference
gene. Data are from individual dams (n = 6–8 each).
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α-GalCer inhibits PPARγ activation at the maternal-fetal interface that is restored
by rosiglitazone
Since treatment with rosiglitazone reduced the rate of α-GalCer-induced late
PTB, we investigated whether α-GalCer was inhibiting PPARγ genes at the maternalfetal interface and whether this inhibition could be abrogated by rosiglitazone.
Expression profiles of the PPAR pathway-related genes were different between
myometrial and decidual tissues in all of the groups (Figure 29E).

We specifically

focused on PPARγ target genes. Adipocyte-specific fatty acid binding protein (Fabp4)
and fatty acid transport protein 4 (Fatp4) are recognized as indicators of PPARγ
activation (242, 243). Our array data showed that rosiglitazone up-regulated Fabp4 in
myometrial tissues and Fatp4 and Cyp410 in decidual tissues while α-GalCer downregulated such genes; therefore, we validated the expression of Fabp4 and Fatp4 in
these tissues.

Administration of α-GalCer down-regulated expression of Fabp4 in

myometrial tissues; however, treatment with rosiglitazone resulted in up-regulation to
basal levels (Figure 29F). Administration of α-GalCer down-regulated expression of
Fatp4 in myometrial tissues and tended to down-regulate expression of Fatp4 in
decidual tissues (Figure 29G). Treatment with rosiglitazone partially restored Fatp4
expression in decidual tissues but not in myometrial tissues (Figure 29G).

These

results demonstrate that rosiglitazone prevents α-GalCer-induced late PTB by restoring
PPARγ activation at the maternal-fetal interface.
α-GalCer induces an expansion of activated CD1d-restricted iNKT cells in
decidual tissues that is blunted by rosiglitazone
Next, we investigated whether α-GalCer caused a systemic and local (maternalfetal interface) expansion of iNKT cells and whether rosiglitazone reduced such
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Figure 30: Administration of α-GalCer induces an expansion of activated CD1d-restricted
iNKT cells in decidual tissues that is blunted by rosiglitazone. (A) Gating strategy used to
identify CD1d-restricted iNKT cells (CD1d tetramer+DX5+NK1.1+TCRβ+ cells) in decidual
tissues. (B) Number of CD1d-restricted iNKT cells in decidual tissues from mice injected with
DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer + Rosi. Data are from individual dams (n =
6–8 each). (C) Immunophenotyping of activation markers CD69, CD44, and IL-4 in CD1drestricted iNKT cells in decidual tissues from mice injected with DMSO, α-GalCer, Rosi, or αGalCer + Rosi. The shaded graph represents the autofluorescence control, and the open graph
represents the fluorescence signal from CD1d-restricted iNKT cells. (D and E) Number of
CD69+CD44+ and IL-4+ CD1d-restricted iNKT cells in decidual tissues from mice injected with
DMSO, α-GalCer, Rosi, or α-GalCer + Rosi. Data are from individual dams (n=6–8 each).

expansions. Because NKT-cell function and subsets are tissue- or organ-specific (244246), we used a combination of markers including CD1d-Tetramer loaded with α-
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GalCer, DX5, NK1.1, and TCRβ to identify iNKT cells (Figure 30A). Administration of αGalCer

caused

an

expansion

of

CD1d-restricted

iNKT

cells

(CD1d

Tetramer+DX5+TCRβ+NK1.1+ cells) in decidual tissues; yet, this expansion was blunted
by treatment with rosiglitazone (Figures 30B). In contrast, administration of α-GalCer
did not significantly alter the number of CD1d-restricted iNKT cells in the liver (Figure
31A), myometrium (Figure 31B), spleen (Figure 31C), or ULN (Figure 31D).

Figure 31: CD1d-restricted iNKT cells in the liver, myometrium, spleen, and lymph nodes.
Number of CD1d-restricted iNKT cells in the liver (A), myometrium (B), Spleen (C), and uterine
lymph nodes (D) from mice injected with DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer +
rosiglitazone. Data are representative of individual dams, n=6-8 each.

We also evaluated whether α-GalCer-expanded decidual iNKT cells were
activated and, in such a case, whether rosiglitazone treatment reduced the number of
these cells. Activated iNKT cells express CD69 and CD44, and release Th1 (e.g., IFNγ)
and Th2 cytokines (e.g., IL4) (216, 218, 247).
Decidual CD1d-restricted iNKT cells expressed CD69, CD44, IL4 (Figure 30C),
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and, to a lesser extent, IFNγ (Figure 32). Administration of α-GalCer increased the
number of activated CD69+CD44+ and IL4+CD1d-restricted iNKT cells in decidual
tissues, both of which were reduced by treatment with rosiglitazone (Figure 30D&E).
No significant effects were seen in IFNγ+CD1d-restricted iNKT cells upon α-GalCer
and/or rosiglitazone administration (Figure 32). Together, these data demonstrate that
rosiglitazone prevents α-GalCer-induced late PTB by reducing activated CD1drestricted iNKT cells at the maternal-fetal interface.
Figure 32: IFNγ+ CD1d-restricted iNKT cells in
decidual tissues. Number of IFNγ+ CD1drestricted iNKT cells in decidual tissues from
mice
injected
with
DMSO,
α-GalCer,
rosiglitazone (Rosi), or α-GalCer + rosiglitazone.
Data are from individual dams, n=6-8 each.

α-GalCer induces activation of conventional CD4+ T cells in myometrial tissues
that is reduced by rosiglitazone
iNKT cells bridge the innate and adaptive limbs of the immune system; therefore,
activation of iNKT cells triggers both innate and adaptive immune responses (248).
Indeed, activation of CD1d-restricted iNKT cells by administration of α-GalCer in nonpregnant mice induces expression of CD69, an early activation marker, in T cells and B
cells (249-252). We then investigated whether administration of α-GalCer in the third
trimester induced T-cell activation in myometrial and decidual tissues, and whether this
activation was reduced after treatment with rosiglitazone. Several markers of T-cell
activation including CD25, CD40L, PD1, CD69, and CTLA-4 were determined in
conventional CD4+ and CD8+ T cells. Administration of α-GalCer led to the activation of
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conventional CD4+ T cells demonstrated by the expression of CD25 and PD1 in
myometrial tissues, which was reduced by treatment with rosiglitazone (Figures 33A-C).
Figure 33: Administration of
α-GalCer induces activation
of CD4+ T cells in myometrial
tissues that is reduced by
rosiglitazone.
(A)
Gating
strategy used to identify
activated
CD4+
T
cells
+
+
(CD3 CD4
cells)
in
myometrial
tissues.
Immunophenotyping
of
activation markers CD25 and
PD1 in CD4+ T cells in
myometrial tissues from mice
injected with DMSO, α-GalCer,
rosiglitazone (Rosi), or αGalCer + Rosi. The shaded
graphs
represent
the
autofluorescence control, and
the open graph represents the
fluorescence signal from CD4+
T cells. (B and C) Proportion of
CD25+CD4+ T cells and
PD1+CD4+
T
cells
in
myometrial tissues from mice
injected with DMSO, α-GalCer,
Rosi, or α-GalCer + Rosi. Data
are from individual dams (n=6–
8 each). (D & E) Proportion of
CD25+CD8+ T cells and
T
cells
in
CD69+CD8+
myometrial tissues from mice
injected with DMSO, α-GalCer,
Rosi, or α-GalCer + Rosi. Data
are from individual dams (n =
6–8 each).

This treatment also reduced basal CD8+ T cell activation in myometrial tissues
(Figures 33D & E). No significant effects were seen in activated CD4+ and CD8+ T cells

80
upon α-GalCer administration in decidual tissues (Figure 34). These data demonstrate
that rosiglitazone prevents α-GalCer-induced late PTB by reducing activated T cells in
the myometrial tissues.

Figure 34: Activated CD4+ and CD8+ T cells in decidual tissues. (A) Proportion of
CD25+CD4+ T cells and PD1+CD4+ T cells in decidual tissues from mice injected with DMSO,
α-GalCer, rosiglitazone (Rosi), or α-GalCer + rosiglitazone. (B) Proportion of CD25+CD8+ T
cells and CD69+CD8+ T cells in decidual tissues from mice injected with DMSO, α-GalCer,
rosiglitazone, or α-GalCer + rosiglitazone. Data are from individual dams, n=6-8 each.

α-GalCer induces innate immune activation at the maternal-fetal interface that is
attenuated by rosiglitazone
iNKT-cell activation also initiates innate immune responses mediated by
macrophages and neutrophils (251, 253) as well as induces the full maturation of DCs
manifested by the expression of MHC class II, IFNγ production, and APC function (254).
First, we investigated whether administration of α-GalCer induces macrophage
activation in myometrial and decidual tissues, and whether this activation was reduced
after treatment with rosiglitazone. Macrophage activation is a complex process since it
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depends on the nature of the stimulus and the microenvironment where these cells
exhibit their function (255, 256).
The classical M1/M2 macrophage paradigm provides useful markers (Arg1, iNOS,
IL10, and IFNγ) for macrophage activation (257-260); therefore, we evaluated the
expression

of

these

molecules

in

myometrial

and

decidual

macrophages

(CD11b+F4/80+ cells). Administration of α-GalCer increased the number of decidual

Figure 35: Administration of α-GalCer induces activation of innate immune cells at the
maternal–fetal interface that is blunted by rosiglitazone. (A) Number of activated IFN-γ+IL10+ macrophages in decidual tissues from mice injected with DMSO, α-GalCer, rosiglitazone
(Rosi), or α-GalCer + Rosi. Data are from individual dams (n = 6–8 each). (B) Number of
activated IL-10+Arg1+ macrophages in decidual tissues from mice injected with DMSO, αGalCer, Rosi, or α-GalCer + Rosi. Data are from individual dams (n = 6–8 each). (C) Number
of activated IFN-γ+ neutrophils in decidual tissues from mice injected with DMSO, α-GalCer,
Rosi, or α-GalCer + Rosi. Data are from individual dams (n = 6–8 each). (D) Number of IFN-γ+
mature DCs in decidual tissue from mice injected with DMSO, α-GalCer, Rosi, or α-GalCer +
Rosi. Data are from individual dams (n = 6–8 each).
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macrophages that produce both IFNγ and IL10 (Figure 35A). Also, administration of αGalCer increased the number of decidual macrophages that express both Arg1 and
IL10; yet, this increase did not reach statistical significance (Figure 35B). In both cases,
treatment with rosiglitazone reduced the number of activated macrophages (Figures
35A & B).

Administration of α-GalCer did not have such effects on myometrial

macrophages (data not shown).
Next, we investigated whether administration of α-GalCer induces neutrophil
activation in myometrial and decidual tissues, and whether this activation was reduced
after treatment with rosiglitazone.

IFNγ expression is an indicator of neutrophil

activation (261, 262). In the study herein, we demonstrated that administration of αGalCer increased the expression of IFNγ by neutrophils in myometrial and decidual
tissues, and this effect was reduced by treatment with rosiglitazone (Figures 35C &
Figure 36).
Figure 36: Number of IFNγ+ neutrophils
in myometrial tissues from mice
injected
with
DMSO,
α-GalCer,
rosiglitazone (Rosi), or α-GalCer +
rosiglitazone. Data are from individual
dams, n=6-8 each.

Lastly, we investigated whether administration of α-GalCer in the third trimester
induced DC maturation in decidual tissues, and whether this process was blocked by
administration of rosiglitazone. Administration of α-GalCer increased the number of
mature DCs (CD11b+CD11c+DEC205+ cells; data not shown) and the number of IFNγ+
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mature DCs in decidual tissues (Figure 35D).

Treatment with rosiglitazone did not

reduce the number of mature DCs (data not shown); however, it reduced the number of
IFNγ+ mature DCs in decidual tissues (Figure 35D).

Taken together, these data

demonstrate that rosiglitazone prevents α-GalCer-induced late PTB by attenuating
innate immune activation at the maternal-fetal interface.
α-GalCer induces a pro-inflammatory microenvironment at the maternal-fetal
interface that is partially attenuated by rosiglitazone
Whereas iNKT-cell activation induces the expression of inflammatory genes
(214, 215), PPARγ activation suppresses their expression (224, 225).

We next

investigated whether α-GalCer up-regulated inflammatory genes at the maternal-fetal
interface, and whether this up-regulation was suppressed by rosiglitazone. Expression
profiles of inflammation-related genes were different between decidual and myometrial
tissues (Figure 37A). As expected, several genes were up-regulated in both types of
tissue upon administration of α-GalCer (α-GalCer vs. DMSO; Figure 37A). Some of
these genes were down-regulated after treatment with rosiglitazone, mainly in decidual
tissues (α-GalCer+Rosi vs. α-GalCer; Figure 37A). We selected some of the downregulated genes after treatment with rosiglitazone and validated their expression.
Administration of α-GalCer up-regulated the expression of Ccl1, Ccl2, Ccl12, and Tnf in
decidual tissues; however, these genes were down-regulated after treatment with
rosiglitazone (Figure 37B). Administration of α-GalCer also up-regulated expression of
Ccl2 and Ccl12 in myometrial tissues; however, only Ccl2 was significantly downregulated after treatment with rosiglitazone (Figure 37C). These data demonstrate that
rosiglitazone prevents α-GalCer-induced late PTB by partially reducing the proinflammatory milieu at the maternal-fetal interface.

84
A

B

Figure 37: Administration of αGalCer
induces
a
proinflammatory
microenvironment at the maternal–fetal
interface
that
is
partially
attenuated by rosiglitazone. (A)
A heat map visualization of
cytokine and chemokine gene
expression in myometrial and
decidual tissues from dams
injected with DMSO, α-GalCer,
rosiglitazone (Rosi), or α-GalCer +
Rosi. Data are from individual
dams (n = 4 each). (B) mRNA
expression of Ccl1, Ccl2, Ccl12,
and Tnf in decidual tissues.
Negative
∆Ct
values
were
calculated using Actb as a
reference gene. Data are from
individual dams (n=6–8 each). (C)
mRNA expression of Ccl2 and
Ccl12 in myometrial tissues.
Negative ∆Ct values (B and C)
were calculated using Actb as a
reference gene. Data are from
individual dams (n = 6–8 each).

85
α-GalCer induces a maternal systemic pro-inflammatory response,
rosiglitazone triggers a maternal systemic anti-inflammatory response

yet

Next, we evaluated the effects of α-GalCer and rosiglitazone on cytokine serum
concentration in maternal circulation at 6h or 24h (prior to α-GalCer-induced late PTB)
post α-GalCer administration.

Six hours post α-GalCer administration, the

concentrations of all measured cytokines, except GMSCF, IL3, IL4, and IL7, were
increased when compared to DMSO or rosiglitazone controls; however, none of these
cytokines were reduced after treatment with rosiglitazone (data not shown). Twentyfour hours post α-GalCer administration, the pro-inflammatory cytokines —IFNγ,

Figure 38: Administration of α-GalCer induces a maternal systemic proinflammatory
response, yet rosiglitazone drives a maternal systemic anti-inflammatory response.
Pregnant mice were injected with DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer + Rosi.
Serum concentrations of proinflammatory (A) and anti-inflammatory (B) cytokines/chemokines
were determined 24 h after the initial injection. Data are from individual dams (n = 8–9 each).
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IL2, CXCL9, CXCL10, CCL2, and CCL5 — were increased when compared to DMSO or
rosiglitazone controls (Figure 38A).
Treatment with rosiglitazone did not reduce these high concentrations; indeed, it
further increased the concentrations of IFNγ, CXCL9, CXCL10, and CCL2 (Figure 38A).
Interestingly, dams injected with α-GalCer that were subsequently treated with
rosiglitazone had increased concentrations of anti-inflammatory cytokines IL10, IL17,
IL3, IL5, GSCF, and IL12p40 when compared to mice injected with only α-GalCer
(Figure 37B). These data demonstrate that rosiglitazone prevents α-GalCer-induced
late PTB by enhancing a maternal systemic anti-inflammatory response.
Spontaneous preterm labor/birth is associated with an increased proportion of
activated iNKT-like cells in decidual tissues
Up to this point, our results demonstrated that activation of decidual iNKT cells
leads to late PTB in mice; however, it was unknown whether these cells are increased
during preterm labor/birth in humans. iNKT cells are present in first-trimester decidua
(263); therefore, we hypothesized that preterm labor will be associated with an increase
in the proportion of activated iNKT cells at the maternal-fetal interface. In humans, the
maternal-fetal interface includes: 1) the decidua parietalis that lines the uterine cavity
not covered by the placenta and is in juxtaposition to the chorion leave, and 2) the
decidua basalis, located in the basal plate of the placenta where it is invaded by
interstitial trophoblasts (Figure 39A). The gating strategy used to determine activated
iNKT-like cells (CD69+CD56+CD3+CD19-CD14-CD15- cells) in decidual tissues is
shown in Figure 39B. In the decidua basalis and parietalis, activated iNKT-like cells
were greater in women who underwent spontaneous term labor (TIL) or preterm labor
(PTL) when compared to women who did not undergo labor at term (TNL) or preterm
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(PTNL), respectively (Figure 39C). In the decidua basalis, activated iNKT-like cells
were more abundant in PTL samples than in TIL samples (Figure 39C).

Further

immunophenotyping of decidual samples (TIL and PTL, n=4 each) revealed that
activated iNKT cells (CD3+Vα24Jα18TCR+CD69+ cells; Figure 39D) were present at
proportions similar to previously identified activated iNKT-like cells (CD3+CD56+CD69+
cells) (Figure 39B).

Figure 39: Spontaneous preterm labor/birth is associated with an increased proportion of
activated iNKT-like cells in decidual tissues. (A) Schematic representation showing the
decidua basalis and decidua parietalis. (B) Gating strategy used to identify activated iNKT-like
cells (CD69+CD56+CD3+CD19−CD14−CD15− cells) in human decidual tissue. (C) Activated
iNKT-like cells in the decidual basalis or decidual parietalis from women who underwent
spontaneous TIL or spontaneous PTL. Controls included samples from women who delivered at
term (TNL) or preterm (PTNL) without labor. Data are from individual women: n = 7 for TNL, n =
26 for TIL, n = 13 for PTNL, and n = 14 for PTL. (D) Identification of CD3+Vα24Jα18TCR+CD69+
cells in PTL decidual tissues. (E) Identification of activated iNKT-like cells in the decidua
parietalis by confocal microscopy. Nuclei are blue (DAPI), CD3+ cells are red (Alexa Fluor 594),
CD56+ cells are magenta (allophycocyanin), and CD69+ cells are green (FITC). White arrows
denote activated NKT cells. Scale bar, 20μm.

Since we did not use the iNKT marker, Vα24Jα18TCR, in our initial
immunophenotyping, we cannot refer to these as iNKT cells and have instead termed

88
them iNKT-like cells. Localization of activated iNKT-like cells (CD3+CD56+CD69+DAPI+
cells; white arrows) in the decidua parietalis is shown in Figure 39E. This last set of
data demonstrates that activated iNKT-like cells in human decidual tissues are linked to
spontaneous preterm labor/birth.
Discussion
Sterile intra-amniotic inflammation is more frequent than microbial-associated
intra-amniotic inflammation in patients with spontaneous preterm labor (21, 264).
Sterile inflammation is initiated by alarmins (22) and such danger signals are potent
activators of iNKT cells (212, 213); therefore, we hypothesized that these innate
lymphocytes participate in the pathophysiology of sterile inflammation-related preterm
labor/birth. Using a highly-affine iNKT-cell ligand, α-GalCer (222), we provided direct
evidence that iNKT-cell activation is implicated in the mechanisms that lead to
inflammation-induced preterm labor in the absence of infection. Indirect evidence for
the role of iNKT cells in the pathophysiology of inflammation-induced preterm labor was
based on two facts: (1) iNKT-cell null mice (Ja18-/- mice) are more resistant to
endotoxin-induced PTB than wild type mice (265), and (2) adoptive transfer of decidual
iNKT cells into iNKT-cell null mice injected with an endotoxin rapidly induces the onset
of PTB (266). However, endotoxins are not iNKT-cell ligands and can only indirectly
activate autoreactive iNKT cells through TLR signaling and the release of IL12 by APCs
(217, 220, 267). Therefore, indirect activation of iNKT cells by an endotoxin resembles
Gram-negative bacteria-related preterm labor, and direct activation via an iNKT-cell
ligand could explain sterile inflammation-related preterm labor.
Administration of α-GalCer in the second trimester did not result in pregnancy
loss. This finding is not surprising since the mechanisms that lead to pregnancy loss

89
differ from those implicated in preterm labor/birth. For example, during the second
trimester, pregnancy maintenance depends on regulatory T cells (Tregs), as their
depletion causes pregnancy loss (268, 269). In the third trimester, however, depletion
of Tregs does not cause preterm labor/birth (270). These data led us to suggest that
during the third trimester, Treg-independent regulatory mechanisms such as iNKT-cell
quiescence may be responsible for pregnancy maintenance.

Further studies are

needed to investigate the mechanisms whereby iNKT cells remain quiescent in order to
maintain pregnancy until term.
Late preterm neonates survive, yet are at a higher risk for morbidity and mortality
than term neonates (271, 272).

In our model of α-GalCer-induced late PTB, we

consistently showed that pups did not die in utero; yet, they were bradycardic and died
shortly after birth.

This finding indicated that fetal compromise was occurring

simultaneously with the process of preterm labor rather than as a direct cause of
prematurity. Because NKT cells appear at day 5 after birth (273), we are confident that
the adverse neonatal outcomes are due to the effects of α-GalCer administration on the
maternal immune system and at the maternal-fetal interface rather than as a direct
effect on the pups.
Herein, we demonstrated for the first time that α-GalCer inhibits PPARγ
activation at the maternal-fetal interface, which is concordant with a previous study
demonstrating that PPARγ expression is reduced in intrauterine tissues in term
parturition (274).

These data suggest that PPARγ activation, a suppression of

inflammatory genes, is required for late pregnancy maintenance and its inhibition
participates in the normal and pathological processes of labor.

Conversely,

rosiglitazone causes PPARγ activation and prevents α-GalCer-induced late PTB. Our
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unpublished results demonstrated that this PPARγ agonist also prevents endotoxininduced PTB (275). Therefore, targeting the PPARγ pathway could represent a new
strategy to prevent both sterile and microbial inflammation-related preterm labor/birth.
An expansion of decidual iNKT cells was observed shortly after α-GalCer
administration. This is consistent with a previous study demonstrating that iNKT-cell
activation is observed only 4 hours post-αGalCer administration (241).

A systemic

expansion of iNKT cells occurs 2-3 days after α-GalCer administration (276), which
explains why in our study we did not observe such an event. We also demonstrated
that treatment with rosiglitazone attenuated the α-GalCer-induced iNKT-cell expansion
in decidual tissues.

It is likely that rosiglitazone is interfering with iNKT-cell

development instead of causing cell death, since this drug did not reduce cell viability in
decidual cells (Figure 40); yet, it caused a reduction of iNKT cells in the liver (Figure
31A). The previous hypothesis is supported by the fact that PPARγ activation regulates
CD1d molecules (242, 277), which are constitutively expressed by APCs (278, 279) and
can modulate iNKT-cell responses (220, 280). Therefore, it is probable that indirect
suppression of iNKT-cell expansion and activation is the primary mechanism whereby
rosiglitazone prevents PTB in our model.

Consequently, we investigated whether

rosiglitazone could be suppressing activation/maturation of T cells, macrophages,
neutrophils, and DCs, all of which are implicated in the pathophysiology of preterm
labor/birth (281-283).

91
Figure 40: Viability of
decidual
cells
after
treatment
with
rosiglitazone. Cell viability of
decidual leukocytes (CD45+
cells) was determined by flow
cytometry after 6 hrs of
incubation
with
DMSO
(rosiglitazone
vehicle),
rosiglitazone, or without either
treatment (control).

T cells seem to be implicated in the process of preterm parturition (282). This
concept was based on the fact that mice deficient in T and B cells (Rag1-/-) are more
susceptible to endotoxin-induced PTB than wild type mice, and this susceptibility is
reversed upon transfer of CD4+ T cells (284). These findings led us to suggest that
CD4+ T cells play a regulatory role in late pregnancy (282); however, their function has
not been established by depleting these cells prior to preterm labor.

Recently, we

proposed that the activation of effector CD4+ T cells is involved in the physiological
process of parturition (9, 10, 285).

Herein, we provide further evidence to this
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hypothesis by demonstrating that activation of CD4+ T cells occurs prior to αGalCerinduced PTB. We also demonstrated that rosiglitazone reduced αGalCer-induced T-cell
activation.

This finding is consistent with previous studies demonstrating that

pretreatment with PPARγ ligands reduces T-cell activation and proliferation in vitro (286,
287). Taken together, these data support the hypothesis that CD4+ T cell activation
participates in the physiological and pathological processes of parturition and suggests
that targeting the PPARγ pathway attenuates activation of the adaptive limb of
immunity, rescuing preterm labor/birth.
The role of macrophages in the mechanisms that lead to preterm labor is wellestablished since the depletion of these innate cells protects mice from endotoxininduced PTB (15). The study herein demonstrated increased macrophage activation
prior to αGalCer-induced PTB, which supports a central role for these innate immune
cells in the pro-inflammatory milieu that accompanies the sterile processes of preterm
parturition. We also demonstrated that treatment with rosiglitazone inhibits macrophage
activation in decidual tissues. Prior research, in line with our study, has shown that
PPARγ expression is up-regulated in activated macrophages and that treatment with
rosiglitazone, or natural PPARγ agonists, down-regulates the expression of iNOS,
inhibits migration, and suppresses the release of inflammatory cytokines by these cells
(224, 288, 289).
Unlike macrophages, the depletion of neutrophils does not prevent endotoxininduced PTB; yet, it ameliorates the pro-inflammatory response in the uterine-placental
tissues (290). Herein, we demonstrated that activation of neutrophils occurs prior to
αGalCer-induced preterm birth, which suggests that although neutrophils are not
essential, they participate in the pro-inflammatory milieu that accompanies the
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pathological process of preterm parturition.

We also found that treatment with

rosiglitazone reduced α-GalCer-induced neutrophil activation. This is in accord with a
previous in vitro study which demonstrated that PPARγ agonists (troglitazone and 15deoxy-∆12,14 prostaglandin J2) diminished the chemotactic response of neutrophils and
suppressed their production of pro-inflammatory cytokines (291).
In addition, administration of α-GalCer resulted in the expression of IFNγ by
mature decidual DCs. These innate immune cells seem to contribute to the initiation of
T cell responses during the physiological and pathological processes of parturition (282,
284, 285, 292, 293).

Herein, we provide evidence to support this hypothesis by

demonstrating that mature DCs participate in the inflammatory process that leads to
inflammation-related preterm labor/birth.

We also showed that treatment with

rosiglitazone blunted the α-Galcer-induced IFNγ expression in mature DCs but did not
interfere in their maturation. This is consistent with a previous study demonstrating that
rosiglitazone does not interfere with the maturation of DCs in vitro nor affects their ability
to activate T cells in vivo; however, this PPARγ agonist modifies DC differentiation by
reducing their secretion of cytokines (294).
Collectively, our results demonstrated that prior to α-Galcer-induced PTB there
was an activation of innate immune cells at the maternal-fetal interface, which were
suppressed by PPARγ activation, rescuing inflammation-related preterm labor/birth.
Besides regulating immune cell activation at the maternal-fetal interface, rosiglitazone
attenuated the expression of pro-inflammatory cytokine/chemokines implicated in the
pathophysiology of inflammation-related preterm labor (295-303).

The suppressive

effect of PPARγ agonists on cytokine expression has been previously demonstrated in
vitro (304). These data demonstrate that PPARγ activation regulates the local pro-
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inflammatory milieu associated with preterm labor/birth.
The systemic anti-inflammatory activity of rosiglitazone was also demonstrated in
this study.

This finding is in concordance with our unpublished data showing that

treatment with rosiglitazone increases the serum concentration of IL5 and CXCL9 in
dams injected with an endotoxin (Yi Xu, et al; unpublished data).

The

immunomodulatory action of rosiglitazone through the up-regulation of anti-inflammatory
cytokines was previously demonstrated when PMA-stimulated THP-1 cells were
incubated with PPARγ agonists and an increased production of IL1RA was observed
(305). In our study, the anti-inflammatory effect of rosiglitazone was observed at 24h,
but not at 6h, after α-GalCer administration, suggesting that said effect takes place after
regulating the local microenvironment.
To conclude, we identified activated iNKT-like cells at the human maternal-fetal
interface in term and preterm gestations. Activated iNKT-like cells were more abundant
in the decidual basalis of women who underwent preterm labor than in those who
delivered preterm without labor, suggesting that these cells are localized in a fetal
antigenic site. The majority (92%) of our samples came from women who underwent
spontaneous preterm labor and did not present intra-amniotic infection, which further
supports the hypothesis that activated iNKT-like cells are implicated in the sterile
process of inflammation that leads to preterm labor/birth.
In summary, this study demonstrates that in vivo iNKT-cell activation leads to late
preterm labor/birth by activating innate and adaptive immune cells as well as decidual
and myometrial cells at the maternal-fetal interface. We also showed that iNKT-cell
activation exerts this effect by inducing a maternal systemic pro-inflammatory response.
Finally, we demonstrated that PPARγ activation prevents prematurity by modulating the
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local and systemic inflammatory milieu that accompanies preterm labor.

Further

exploration of the PPARγ pathway and its regulation in pregnancy complications may
lead to novel therapeutic approaches that can improve neonatal outcomes.
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CHAPTER 7 - THE ROLE OF SENESCENCE IN THE PATHOPHYSIOLOGY OF
STERILE INFLAMMATION
Introduction
Cellular senescence, first described in 1965 as limited replicative capacity of a
normal cell (306), is characterized by growth arrest, resistance to apoptosis, altered
gene expression and, in some cases, by formation of heterochromatic foci, telomere
shortening, and increased secretion of signaling molecules (307). Under physiological
conditions, senescence cells, immuno-recognized by T helper cells (308), are thought to
recruit phagocytes, promoting clearance and regeneration that occur during tissue
remodeling in embryogenesis and upon tissue damage (309). However, persistence or
deficient clearance of senescent cells can lead to accumulation of cellular damage,
which is associated with multiple disorders (309).
The initial observation that uterine-specific p53 deficiency leads to uterine
senescence and causes preterm delivery in 50% of mice (310) provided the first
indication of senescence-associated preterm birth. The follow-up studies showed that
increased mTORC1 signaling (31) and oxidative stress (311) predispose these mice to
preterm birth, which reaches 100% with a mild inflammatory insult (312). Additionally,
deciduae obtained from women who underwent preterm labor stained positive for
senescence-associated

β-galactosidase

(SA-

β-gal)

and

exhibited

higher

immunoreactivity for the mTORC1 signaling marker pS6 as well as for labor-promoting
enzyme cyclooxygenase 2 (COX2) when compared to term labor cases and non-labor
controls (312).

It has been proposed that, in addition to decidual senescence,

senescence of the chorioamniotic membranes may promote labor (313).

Although

senescence of the chorioamniotic membranes was documented in preterm prelabor
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rupture of membranes (pPROM) (314), it requires clearer characterization in the context
of spontaneous preterm labor.

The evidence presented herein stipulates that the

chorioamniotic membranes of patients who undergo spontaneous preterm labor exhibit
both exaggerated senescence, as confirmed by the expression of senescenceassociated genes and increased reactivity of SA- β-gal, and up-regulated mTOR
signaling, as indicated by elevation of pS6 in the chorioamniotic membranes.
Materials and Methods
Human subjects, clinical specimens, and definitions
The chorioamniotic membrane samples were collected at the Perinatology
Research Branch, an intramural program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, National Institutes of Health, U. S.
Department of Health and Human Services (NICHD/NIH/DHHS), Wayne State
University (Detroit, MI, USA), and the Detroit Medical Center (Detroit, MI, USA). All
participants provided written informed consent.
Table 9: Demographical characteristics of the patients whose samples were used for RTPCR in the Senescence study
Age, y
Body mass index, kg/m2
Gestational age at
delivery, wk
Birth weight, g
Race
African-American
Caucasian
Hispanic
Other
Primiparity
C-section
Acute Chorioamnionitis

TNL
(n=28)

TIL
(n=28)

PTNL
(n=27)

PTL
(n=26)

26.5
(22.8-29.3)
28.3
(25.3-35.4)
39.3
(39-39.7)
3293
(3104-3633)

22.5
(20-25)
22.7
(19.8-25.9)
39.7
(39.2-40.2)
3238
(3076-3490)

24
(21-27)
27.3
(23.9-34.1)
32.9
(29.8-34.2)
1480
(908-1865)

23
(20-25)
22.1
(20-25.2)
33.8
(31.3-35.3)
1980
(1558-2155)

22 (78.5%)
3 (10.7%)
1 (3.6%)
2 (7.1%)
1 (3.6%)
28 (100%)
0 (0%)

22 (78.5%)
2 (7.1%)
3 (11%)
1 (3.6 %)
5 (17.8%)
0 (0%)
0 (0%)

26 (96.2%)
0 (0%)
0 (0%)
1 (3.7%)
4 (14.8%)
27 (100%)
0 (0%)

24 (92.3%)
1 (3.8%)
0 (0%)
1 (3.8%)
2 (8%)
8 (31%)
0 (0%)

p value

0.047
0.001
<0.001
<0.001

NS
NS
<0.001
NA

Maternal age, body mass index, gestational age at delivery, birth weight, race, Primiparity, C-section, and
acute chorioamnionitis are listed as mean (range) or n (%). Either Kruskal-Wallis test or Chi-square test
was used to analyze the statistical differences between the study groups (TNL, TIL, PTNL, and PTL).
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The collection and utilization of biological materials was approved by the
Institutional Review Boards of the NICHD and Wayne State University. The collected
samples were categorized based on the labor status of the patients: 1) spontaneous
term labor (TIL) (n=40); 2) term delivery without labor (TNL) (n=35); 3) spontaneous
preterm labor (PTL) (n=37); and 4) preterm delivery without labor (PTNL) (n=36). The
demographic characteristics of these patients are shown in Tables 9 & 10. Labor was
defined as the presence of regular uterine contractions at a minimum frequency of two
every 10 minutes associated with cervical changes leading to delivery (315, 316).
Table 10: Demographical characteristics of the patients whose samples were used for
expression array and SA-β-gal assays in the Senescence study
TNL
(n=7)

TIL
(n=8)

PTNL
(n=8)

PTL
(n=9)

p value

29
(26-29)

22
(18.8-24.3)

29
(25.5-35.3)

23
(19-27)

NS

Body mass index,
kg/m2

34.1
(30.2-36.6)

23.5
(21.3-24.3)

27.6
(22.1-45.8)

25.2
(23.4-32)

NS

Gestational age at
delivery, wk

39.3
(39.2-39.7)

39.4
(39.2-39.6)

30.2
(29.3-30.7)

34
(33.6-36)

<0.001

3820
(3603-3898)

3256
(3156-3390)

1117
(816.3-1233.8)

2330
(1795-2655)

<0.001

5 (71.4%)
2 (28.6%)
0 (0%)
0 (0%)

8 (100%)
0 (0%)
0 (0%)
0 (0%)

6 (75%)
0 (0%)
0 (0%)
2 (25%)

9 (100%)
0 (0%)
0 (0%)
0 (0%)

NS

C-section

0 (0%)
7 (100%)

3 (37.8%)
0 (0%)

0 (0%)
8 (100%)

Acute Chorioamnionitis

0 (0%)

Age, y

Birth weight, g
Race
African-American
Caucasian
Hispanic
Other
Primiparity

0 (0%)

0 (0%)

1 (11.1%)
4 (44.4%)
0 (0%)

NS
<0.001
NA

Maternal age, body mass index, gestational age at delivery, birth weight, race, Primiparity, C-section, and
acute chorioamnionitis are listed as mean (range) or n (%). Either Kruskal-Wallis test or Chi-square test
was used to analyze the statistical differences between the study groups (TNL, TIL, PTNL, and PTL).

Gene Expression Determination
Frozen chorioamniotic membranes were treated with TRI Reagent ® Solution
(Ambion, Carlsbad, CA, USA), and RNA extraction was performed with RNeasy Mini
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Kits (Qiagen,Valencia, CA, USA), QIAshredders (Qiagen), and RNase-Free DNase Sets
(Qiagen).
Table 11: List of primers used for RT-PCR in the Senescence study
Symbol
P53
CDKN1A (P21)

Gene Name
Tumor Protein p53
Cyclin-Dependent Kinase Inhibitor 1A
V-akt Murine Thymoma Viral Oncogene Homolog 1
AKT1
AT-Hook Protein of GA Feedback 1
AGF1
Interferon Gamma
IFNG
Cyclin E1
CCNE1
Cyclin A2
CCNA2
Cyclin B1
CCNB1
Cyclin-Dependent Kinase 2
CDK2
Fibronectin 1
FN1
Collagen, Type I, Alpha 1
COL1A1
Ribosomal Protein, Large, P0
RPLP0
Beta-Actin
BACT
Glyceraldehyde-3-Phosphate Dehydrogenase
GAPDH
Gene symbol, gene name, assay ID, and lot are listed.

Assay ID
Hs01034249_m1
Hs00355782_m1
Hs00178289_m1
Hs00153126_m1
Hs00989291_m1
Hs01026536_m1
Hs00996788_m1
Hs01030099_m1
Hs01548894_m1
Hs01549940_m1
Hs00164004_m1
Hs99999902_m1
Hs99999903_m1
Hs99999905_m1

Lot
1366180
1347306
1349271
731440
1099507
1320002
1351631
1323891
1356790
1221289
1078329
1347306
1086982
1335169

NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA)
was used to analyze the extracted RNA for concentration and purity whereas the
Bioanalyzer 2100 (Agilent Technologies, Wilmington, DE, USA) was used to assess the
RNA integrity. The RT2 First Strand Kits (Qiagen) were utilized to synthesize cDNA.
RT2 Profiler PCR Array (Qiagen) was used to determine expression of 84 senescenceassociated genes and 6 reference genes (n=7-9).

Based on the pathway analysis

results, gene expression of the selected candidates was confirmed by RT-PCR (n=2528). The RT-PCR experiments were performed on BioMark™ High-throughput qRTPCR system (Fluidigm, San Francisco, CA, USA) and on an ABI 7500 FAST Real-Time
PCR System (Applied Biosystems, Life Technologies Corporation, Foster City, CA,
USA) with TaqMan® gene expression assays (Applied Biosystems) (Table III).
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Western Blot
The immunoblotting was performed as described in Chapter 2. For detecting
phosphorylated S6, 1:500 mouse pS6 Ribosomal Protein (S235/236) (Catalog #2211S,
Cell Signal Technology, Danvers, MA, USA) was used. The housekeeping gene was
probed with 1:5000 β-actin antibody (Catalog # A5316, Clone AC-74, Sigma Aldrich,
Saint Louis, MO). Images were semi-quantified using ImageJ 1.44p software (National
Institute of Health, USA).
Immunohistochemistry
Five-μm-thick sections of formalin-fixed, paraffin-embedded chorioamniotic
membrane tissues (n=7-8) were placed on salinized slides. Anti-Cox2 antibody (1:100,
catalog # NB100-689, Novus Biologicals, Littleton, CO, USA) was used to perform
immunostaining on Leica Bond Max automatic staining system (Leica Microsystems,
Wetzlar, Germany). Antigen retrieval was performed for 10 min with citrate-based Bond
TM Epitope Retrieval Solution I (Leica Microsystems).

Chromogenic reaction of

horseradish peroxidase was detected with Bond™ Polymer Refine Detection Kit (Leica
Microsystems). A PerkinElmer Pannoramic MIDI slide scanner (PerkinElmer, Waltham,
MA, USA) was used to assess the intensity of staining (a semi-quantitative method of
analysis).
Senescence-associated β-galactosidase (SA-β-gal) staining
To detect the presence of SA-β-gala in the fetal membranes, positive cells were
identified as described by Dimri et al. with minor modifications. Fetal membrane roll
sections were frozen in a 25mm x 20mm x 5mm cryomold (Sakura, Torrance, CA, USA)
with O.C.T.

Compound (Fisher Scientific, Hampton, NH, USA); from these blocks,

10µm thick sections were cut using a Leica CM3050 cryostat (Leica Biosystems, Buffalo
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Grove, IL, USA) and mounted on FisherBrand Superfrost microscope slides (Fisher
Scientific, Hampton, NH, USA).

Newly prepared slides were fixed with a cytology

fixative (Leica Biosystems, Buffalo Grove, IL, USA) and kept frozen at -20° C. Sections
were fixed in 0.5% glutaraldehyde in PBS (Life Technology, Carlsbad, CA, USA) (pH
5.5) at room temperature for 15 minutes. The slides were then washed twice in 1mM
MgCl2 in PBS (pH 6.0) for 5 minutes each. After last wash, staining solution containing
1mg/ml X-gal, 1mM MgCl2, 5mM potassium ferricyanide, and 5mM potassium
ferrocyanide in PBS (pH 6.0) was added. Slides were then incubated at 37° C for 24
hours. After incubation, slides were washed twice in 1mM MgCl2 in PBS (pH 7.4),
followed by an additional 30-minute wash with tap water to remove any
crystals/precipitates from the staining solution. Slides were dehydrated with a graded
alcohol bath, counterstained with eosin, mounted with xylene, and cover slipped by
Tissue-Tek SCA (Sakura, Torrance, CA, USA). The slides were scanned using the
Pannoramic MIDI Digital Slide Scanner (PerkinElmer, Inc., Waltham, MA, USA); and
annotations were made by laboratory personnel who then utilized 3DHISTECH software
(3DHISTECH Kft., Budapest, Hungary) to assess the intensity of the SA-β-gal staining.
ELISA
ELISA was performed as described in Chapter 2.

PathScan® Total S6

Ribosomal Protein Sandwich ELISA Kit (Cell Signaling, catalog # 7225C) was used.
Statistical analysis
For senescence-associated gene expression array, Ct values over technical
replicates were averaged, and gene expressions relative to reference (ACTB, B2M,
GAPDH, HPRT1, RPLP0) were quantified by subtracting target gene Ct values from
mean reference gene Ct values within the same sample. Group comparisons were
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conducted via t-test from a linear model. Hierarchical clustering on genes was applied
on the group mean expressions using 1-Pearson correlation as distance metric and
average linkage. Gene set analysis was performed for PTL vs TIL. Gene sets (GO and
KEGG signaling and metabolic pathways) were extracted from R Bioconductor package
“gageData”, and gene symbol to Entrez ID mapping was obtained from package
“org.Hs.eg.db”. The list of genes (ranked by the p value from differential expression
comparison PTL vs TIL), the expression data, the sample classification and the gene
sets

are

formatted

as

input

to

Gene

Set

http://www.broadinstitute.org/gsea/index.jsp) (317).

Enrichment

Analysis

(GSEA:

For confirmatory RT-PCR, Ct

values over technical replicates were averaged, and gene expressions relative to
reference (BACT, GAPDH, RPLPO) were quantified by subtracting target gene Ct
values from mean reference gene Ct values within the same sample. Wilcoxon rank
sum test was used for group comparison. All expression analyses were performed in R
statistical computing environment (http://www.R-project.org/).

Western blot and

immunohistochemistry data were analyzed by Mann-Whitney U test in GraphPad Prism
6 (GraphPad Software, Inc., La Jolla, CA, USA).

Patient demographics data was

performed using Chi-square test for proportions as well as the Kruskal-Wallis test for
non-normally distributed continuous variables in SPSS Statistics 19 (IBM Corporation,
Armonk, NY, USA). A p-value < 0.05 was set as a threshold of statistical significance.
Results
Expression of the senescence-associated genes is dysregulated in preterm
spontaneous labor
To determine whether senescence-associated genes are dysregulated in preterm
labor, we utilized commercially available RT2 Profiler PCR Array (Qiagen). The patient

103
demographics for this experiment are listed in Table 10. Each of the four labor group
tested (preterm labor, term labor, and respective no-labor controls) had a unique
expression profile (Figure 41).

Interestingly, the no-labor groups (PTNL and TNL)

exhibited up-regulation of multiple senescence-associated genes.

Additionally, we

assessed the expression of two labor groups (term and preterm) complicated by acute
infection/inflammation of the chorioamniotic membranes (chorioamnionitis). We found
that the cases with chorioamnionitis exhibited striking increase in expression of
senescence-associated genes (data not shown).

However, we aimed to determine

whether senescence contributes to the pathophysiology of sterile, or infection-free,
inflammation in preterm labor. Therefore, we used the Senescence RT2 Profiler PCR
Array data to perform more detailed comparison in gene expression between normal
term labor (TIL) and pathological preterm labor (PTL).
When comparing expression patterns between preterm and term labor groups by
gene set enrichment analysis (317), we found significant differences between the
groups (p=0.0036), with all of the core enrichment genes being up-regulated in PTL
(Figure 42). We also used the Senescence Array data for pathway analysis to identify
which of the senescence-associated cellular pathways is differentially expressed
between PTL and TIL. We found that the greatest difference in expression (p=0.038)
between term and preterm labor occurred in genes of the p53 pathway (Figure 43).
Considering that disruption of P53 gene induces preterm delivery in mice (310), it
was reassuring to find that preterm labor cases exhibited dysregulated expression of
several genes in the P53 pathway.
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Figure 41: Heat map analysis of the senescence expression array. The chorioamniotic
membranes obtained from women who either delivered at term (TIL and TNL) or preterm (PTL
and PTNL) with or without labor, respectively, were subjected to the Senescence RT2 Profiler
PCR Array (Qiagen). Heat map compares the expression patterns of senescence-associated
genes between the labor groups (n=7-9 per group).
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Figure 42: Gene set enrichment
analysis to compare senescenceassociated
gene
expression
between preterm and term labor.
Senescence RT2 Profiler PCR Array
data was further analyzed by set
enrichment analysis to compare gene
expression patterns between PTL
(marked in red) and TIL (marked in
blue). Nine out of nine core
enrichment genes and seven out of
ten non-core enrichment genes were
up-regulated in PTL (p=0.0036).

Figure 43: P53 pathway is differentially expressed between preterm and term labor.
Pathway analysis revealed significant differences in the P53 signaling pathway between PTL
and TIL groups (p=0.038). Genes highlighted in red were found to be differentially expressed.
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Taken together, these data show that preterm labor is characterized by upregulation of the senescence-associated genes, including the genes in the P53
pathway, when compared to term labor.
Based on our expression array findings, we selected several candidate genes for
expression confirmation using conventional RT-PCR with a greater number of samples
per group (n=25-28). We found that the expression of P53 was significantly downregulated in both preterm and term labor when compared to non-labor controls (p=0.007
and 0.001, respectively) and tended to be down-regulated in preterm labor when
compared to term labor (Figure 44).

Inversely, expression of P21 is significantly

increased in both preterm (p<0.001) and term (p<0.001) labor when compared to the
non-labor controls (Figure 44). P21, also referred to as cyclin-dependent kinase inhibitor
1, is known to inhibit such cell cycle progression genes as cyclin-dependent kinase 2
(CDK2), cyclin-A2 (CCNA2), G2/mitotic-specific cyclin-B1 (CCNB1), and G1/S-specific
cyclin-E1 (CCNE1) (318, 319).

Correspondingly, the expression of CDK2, CCNA2,

CCNB1, and CCNE1 was significantly decreased (p=0.018, <0.001, <0.001, <0.001,
respectively) in preterm labor when compared to preterm delivery without labor (Figure
44). Additionally, expression of CCNA2 and CCNB1 is down-regulated (p=0.02 and
0.009, respectively) in preterm labor when compared to term labor (Figure 44).
Therefore, preterm labor is associated with decreased expression of P53 as well
as increased expression of the cell cycle inhibitor P21 and subsequent decreased
expression of several cell cycle progression genes.
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Figure 44: Expression of P53, P21, and several cycle-progression genes is dysregulated
in preterm labor. The confirmatory RT-PCR (n=25-28) was performed to compare expression
of P53, P21, CDK2, CCNA2, CCNB1, and CCNE1 in the chorioamniotic membranes between
four labor groups (PTNL, PTL, TNL, and TIL).

Senescence-Associated β-galactosidase is more prominent in preterm labor
To determine localization of the senescent cells in the chorioamniotic
membranes, we utilized senescence-associated β-galactosidase staining (SA-β-gal)
which specifically marks senescent cells blue.
We found that the senescent cells were mostly localized to choriodecidua, which
some staining present in the mesenchyme layer as well (Figure 45A). This suggests
that the senescence initiates from the maternal compartment rather than from the fetus.
When we semi-quantified the intensity of the blue signal, we found that the SA-β-gal
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mean intensity was greater in the preterm labor group when compared to term labor
(p=0.0006) or preterm delivery without labor (p=0.06) (Figure 45B). These findings
provide further evidence that preterm labor is associated with pathological senescence
of the chorioamniotic membranes.

A

B

PTL

TIL

PTNL

TNL

p=0.06

p=0.0006

Figure 45: SA-β-gal is increased in preterm labor. Senescence-associated β-galactosidase
staining was performed on the chorioamniotic membranes from four labor groups (n=7-11 per
group). Only senescent cells stain blue (A). Staining intensity was semi-quantified (B).

Heightened mTORC signaling in preterm labor
Next, we aimed to determine whether senescence-induced phenotype of the
chorioamniotic membranes is due to increased mTOR singling, as previously proposed
by Hirota et al. (31). S6 kinase is a down-stream enzyme in mTOR signaling (320); thus
phosphorylated S6 (pS6) is a marker of mTOR activity. We found that, when compared
to the term labor group, the chorioamniotic membranes obtained from women who
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underwent preterm labor contained significantly increased concentration of pS6
(p=0.0047) as determined by ELISA (Figure 46A). Surprisingly, term labor membranes
exhibited significantly higher concentration of pS6 (p=0.0002) than the membranes that
were collected from women who underwent elective Caesarian section at term without
labor, but no significant differences were observed between preterm labor and its
corresponding non-labor control (Figure 46A).

When we attempted to confirm this

finding by Western blot, the identical trend was reveled, although no statistical
significance was reached (Figure 46B).
A

B

Figure 46: Heightened mTOR signaling in preterm labor. Phosphorylated S6 protein (pS6)
was measured by ELISA (A) and by Western blot (B) in the chorioamniotic membranes from
four labor groups (PTNL, PTL, TNL, and TIL).

Cox2 expression is increased in preterm labor
With uterine-specific p53 deficiency in mice, senescence-associated preterm
birth is reversed by oral administration of the selective Cox2 inhibitor celecoxib (310).
Rapamycin is another chemical agent that attenuates senescence, decreases the levels
of Cox2, and rescues preterm birth in this animal model (31). Thus, it was hypothesized
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that senescence promotes labor via activation of Cox-2-dependent prostaglandin
secretion (321). We semi-quantified the immunoreactivity of Cox2 in the chorioamniotic
membranes and found that Cox2 is significantly elevated in preterm and term labor
when compared to non-labor controls, as expected (Figure 47).

It is possible that

senescent cells induce preterm labor by releasing pro-inflammatory mediators, such as
alarmins, which are known to up-regulate expression of Cox2.

Figure 47: Cox2 expression is increased in preterm labor. Cox2 immunostaining was
performed on the chorioamniotic membranes, followed by semi-quantification of the staining
intensity (n=7-8 per group).

Discussion
Major findings of the study
Major findings of the study herein are: 1) Preterm labor is characterized by
dysregulated expression of the senescence-associated genes; 2) The expression of
senescence-associated genes, including the genes in the P53 pathway tends to be
elevated in preterm labor when compared to term labor; 3) P53 gene itself is downregulated in preterm labor, whereas cell cycle inhibitor P21 is up-regulated, while
numerous cell cycle progression genes are down-regulated; 4) SA-β-gal localizes
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senescent cells to choriodecidua and is elevated in preterm labor; 5) mTOR signaling is
heightened in preterm labor when compared to term labor, as determined by
concentration of pS6; 6) Chorioamniotic membranes from patients who underwent
preterm labor exhibit higher immunoreactivity for Cox2 enzyme when compared to nonlabor controls.
Preterm labor is characterized by dysregulated expression of senescenceassociated genes in the chorioamniotic membranes
Our findings demonstrate that dysregulated gene expression characteristic of the
senescent cells occurs in the chorioamniotic membranes of those patients who
underwent spontaneous preterm labor.

Pathological senescence of preterm labor

differs from the natural processes of term labor, as confirmed by differential expression
of multiple senescence-associated genes (Figure 42), including those in the p53
pathway (Figure 43). P53 is best known for being mutated in over half of all cancers, as
it functions to induce cell cycle arrest or apoptosis when the cells get exposed to DNA
damage signals (322).

Paradoxically, P53 is actually capable of both inducing

senescence and of suppressing it (323, 324). The precise regulation of senescence by
P53 is still under investigation, but both up-regulation and down-regulation of P53 as
well as its post-transcriptional modifications can promote senescence (325-327). In the
mouse model of senescence-induced preterm birth, P53 deletion in the uterus causes
senescent phenotype and ultimately leads to labor (310).

We find that P53 is

significantly down-regulated in the chorioamniotic membranes of the patients who
underwent preterm labor when compared to preterm delivery without labor (Figure 44).
Down-regulation of P53 occurs simultaneously with up-regulation of cell cycle inhibitor
P21 and inhibition of its targets CDK2, CCNA2, CCNB1, and CCNE1 (Figure 44).
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Interestingly, it was previously found that knocking out P21 in the animal model of
senescent-induced preterm labor rescues preterm birth (31, 328). Taken together, our
findings confirm that senescence-associated transcription occurs in the chorioamniotic
membranes of patients that eventually undergo preterm birth.
SA-β-gal and mTOR signaling are elevated in the chorioamniotic membranes of
patients who undergo preterm labor
Our findings reveal that the chorioamniotic membranes of patients who undergo
preterm labor are more reactive to SA-β-gal staining that localizes the senescent cells
predominantly to choriodecidua (Figures 45A and B). The senescent phenotype occurs
with heightened mTOR signaling, as evidenced by increased concentration of pS6 in
the chorioamniotic membranes from patients that undergo preterm labor when
compared to labor at term (Figure 46A).

Additionally, preterm labor samples also

exhibit increased immunostaining for Cox2 enzyme when compared to no-labor
controls, although no significant differences between preterm labor and term labor in
terms of Cox2 concentrations were observed (Figure 47).

We hypothesize that

increased mTOR signaling promotes senescent-associated secretory phenotype
(SASP) which leads to secretion of pro-inflammatory alarmins that activate various
immune cells including iNKTs and ultimately initiate the final pathway of parturition that
involves Cox2-mediated heightened uterine contractility. In support of our hypothesis,
p53 was found to promote the release of prototypical alarmin HMGB1 (28, 329), and
both placental membrane aging and HMGB1 signaling were found to be associated with
human parturition (330). Interestingly, the relationship between senescence and sterile
inflammation may be of mutual causation – senescence is known to promote local
inflammation and emergent evidence suggests that inflammation promotes senescence.
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For instance, pro-inflammatory transcription factor NF-κΒ inducible by alarmins was
shown to trigger SASP in the senescent cells (331) and heat shock protein 60 (an
alarmin) was found to induce senescence in monocytes (332). Further research is
required to sort out the complexities of interaction between senescence, sterile
intraamniotic inflammation, and labor.
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CHAPTER 8 - CONCLUSION
The studies described herein demonstrate that sterile inflammation of the
chorioamniotic membranes can be initiated by such alarmins as HMGB1 (Figure 2),
S100A12 (Figure 8), MSU (Figure 15), and HSP70 (Figure 21) as evidenced by
increased expression/ secretion of IL-1β and numerous other pro-inflammatory
mediators, after in vitro treatment.

Although most of the alarmins tested promote

inflammation by NF-κΒ-dependent up-regulation of the inflammasome components,
particularly NLRP3 (Figures 4, 9, & 16), HSP70 seems to act via inflammasomeindependent pathway (Figure 23).
Alarmins have been shown to activate various immune cells, including iNKT cells
(212, 213). We found that activation of iNKT cells in late gestation in turn induces
activation of CD4+ and CD8+ T cells (Figure 34) as well as innate immune cells (Figures
35 & 36) establishing pro-inflammatory microenvironment at the maternal-fetal interface
(Figure 37) and ultimately leading to preterm birth (Figure 27). Therefore, alarmins set
in motion a complex multi-directional immune response that is exaggerated by positive
feedback regulation (Figures 6 & 12), cross-talk between innate and adaptive immunity
(Chapter 6), and mutual causation (Chapter 7).
The alarmins are released during tissue/ cell stress or injury (333). In pregnancy,
the sources of tissue injury and the subsequent release of alarmins can vary from
microbial infection (334-336) to physical trauma (337), maternal stress (338),
environmental exposure/ pollution (339), oxidative damage (340), and cellular
senescence (341). Such range of alarmin-releasing conditions coincides with the mutlifactorial nature of preterm parturition syndrome (180). The studies detailed in Chapter 7
provide evidence for cellular senescence as a potential etiology for preterm birth.
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Specifically, we show that the chorioamniotic membranes obtained from patients who
undergo preterm birth are characterized by dysregulated expression of senescenceassociated genes (Figures 41, 42, 43, & 44), increases SA-β-gal staining in the
choriodecidua (Figure 45), heightened mTOR signaling (Figure 46), and increased
immunoreactivity for Cox2 (Figure 47). Therefore, senescence of the chorioamniotic
membranes may contribute to the release of alarmin at the maternal-fetal interface and
the ensued sterile inflammation characteristic of preterm labor.
In summary, we found that the release of alarmins at the maternal-fetal interface
from senescent, stressed, or injured cells initiates multifaceted pro-inflammatory
cascade that involves activation of both innate and adaptive immune cells including
iNKTs and the release of a multitude of pro-inflammatory cytokines, most notably IL-1β.
This exaggerated inflammatory response initiates the final pathway of parturition that
involves up-regulation of prostaglandin synthase-2 (Figures 13, 19, & 47) and increased
activity of matrix metalloproteinases (Figures 7, 13, & 25) and culminates in preterm
birth (Figure 27) and adverse neonatal outcomes (Figures 14 and 26). More detailed
elucidation of the mechanisms of sterile intraamniotic inflammation will allow us to
search for new therapeutic agents, such as PPARγ agonist rosiglitazone (Chapter 6).
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Preterm birth is defined as the delivery of a live baby prior to the 37th week of
gestation. It is the leading cause of neonatal mortality worldwide. Preterm neonates
are at a higher risk for short- and long-term complications, and prematurity places
significant burden on our society.

Elucidation of the mechanisms that lead to

spontaneous preterm labor will enable development of therapies to prevent this
syndrome.

We aimed to study pathological inflammation that is implicated in the

pathophysiology of spontaneous preterm labor.
Pathological inflammation can be initiated by the activation of innate immunity
either by microorganisms or alarmins, which are endogenous danger signals derived
cellular stress or injury. The inflammatory process initiated by alarmins in the amniotic
cavity is referred to as sterile intraamniotic inflammation because it occurs in the
absence of detectable microbial infection. Sterile intra-amniotic inflammation is more
common than microbial-associated intra-amniotic inflammation in patients with intact
chorioamniotic

membranes

who

undergo

spontaneous

preterm

labor,

and

administration of such alarmins as IL1α or HMGB1 was shown to induce preterm birth.
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Our major aim was to determine whether HMGB1 and three additional alarmins
(S100A12, monosodium urate, and HSP70) are capable of inducing sterile inflammation
of the chorioamniotic membranes and by what molecular mechanism.
Our findings show that HMGB1, S100A12, monosodium urate, and HSP70
greatly increase secretion of pro-inflammatory cytokine IL-1β from the chorioamniotic
membranes and up-regulate other pro-inflammatory pathways leading to collagen
remodeling and synthesis of labor promoting enzyme prostaglandin synthase 2. We
also found that activation of iNKT cells, which was shown to occur via stimulation with
alarmins, induces preterm birth in mice by activating CD4+ and CD8+ T cells as well as
innate immune cells and by establishing pro-inflammatory microenvironment at the
maternal-fetal interface. We also identified rosiglitazone, an anti-inflammatory drug that
dampens iNKT-dependent inflammation, as a potent treatment for preterm labor in
mice. Finally, our data demonstrates that preterm labor is associated with dysregulated
expression of senescence-associated genes and accumulation of senescence markers.
Cellular senescence is characterized by release of pro-inflammatory mediators,
including alarmins, and thus may provide a source of inflammatory signaling in a subset
of patients who undergo preterm parturition.
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